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Front-page picture: illustration of hCES1 as a monomer. The light red area is the N-terminal 
domain, the light blue area is the C-terminal domain, and the light yellow area is the αβ-domain. 
The Z-site is illustrated as an electron cloud around a taurocholate molecule. The active site is 
illustrated as a green colored electron cloud around another taurocholate molecule. The green side 
chains are the side chains, which forms the catalytic triad (SER221, GLU354 and HIS468). The 
dark green colored areas are the catalytic pocket. The red and dark red colored areas are active sites, 
found by two docking analyses with nelfinavir and morphine, respectively. The area pointed out 
with a blue circle is the substrate-binding gorge opening (Bencharit et al., 2006;Rhoades et al., 
2012;Vistoli et al., 2010). The data for the illustration is the .pdb files 2DR0 (hCES1 taurocholate 
complex) and 4AB1 (hCES1 with no substrates) from RCSB.org. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Preface 
Writing scientific reports is an important part of academic work so we decided to write our fifth 
semester project as a scientific literature report containing all the theoretical background with a 
docking experiment. The topic, personalizing treatments using biomarkers to predict the activity of 
human carboxylesterase 1 (hCES1), was chosen due to our interest in the field of Medical Biology 
and due to enzyme activity of hCES1 being a key factor in drug metabolism in the liver. It caught 
our interest that the enzyme activity seems to be imperative for the treatment results which is the 
reason as to why we looked into the different metabolizer profiles with the aim to be able to give 
patients the right dose of medicine.  
Abstract 
Personalized medicine is an evolving medical field aiming to customize treatments through genetic 
profiling, resulting in an improved therapeutic response and minimizing adverse effects. 
Pharmacokinetics refers to the body’s response to xenobiotics. Different responses can be due to 
variations in the genes coding for drug-metabolizing enzymes. Hence, absent, increased or 
decreased enzyme expression can be caused by gene polymorphisms or copy number variants. To 
study the altered efficiency of hCES1 metabolism due to pharmacokinetic changes, it is essential to 
look at the cytochrome P450 (CYP) enzymes. In drug metabolism, six CYP enzymes, including 
CYP2D6 (2D6) and CYP3A4 (3A4), play an imperative role and account for most of the 
metabolism of widely prescribed drugs metabolized in the liver. In this study, 2D6 and 3A4 are 
used as models for human carboxylesterase 1 (hCES1) to explain how the properties of hCES1 can 
be used to benefit the personalization of medicine. hCES1 metabolizes both endogenous and 
xenobiotic compounds. It is expressed in various tissues though mostly in the liver. The CES1 gene 
expression seems to be surprisingly constant between individuals in the human population though 
the enzymatic hCES1 activity differs significantly. This can be due to hCES1 SNPs that are 
identified and classified as possibly damaging to protein structure and function or due to mutations 
in the hCES1 gene resulting in a considerably decreased catalytic function of the hCES1 enzyme. 
hCES1 activity is regulated at genome and enzyme level, exhibiting behavior from both CYP 
models. There are not yet any probes or biomarkers applicable for clinical use, since the one hCES1 
probe that is found, is only tested in hepatic cells. More research is needed, in order to find a probe 
or biomarker that is more accessible. Another approach could be to apply metabolomics, to 
determine the metabotype of a patient.   
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ABC Transporters: ATP-Binding Cassette Transporters, ACAT: Acyl-Coenzyme A Cholesterol 
Acyltransfer, ACE: Angiotensin-Converting Enzyme, ADHD: Attention deficit hyperactive 
disorder, ADR: Adverse Drug Response, ARB: Angiotensin Receptor Blocker, AUC: Area under 
the Curve, CE: Cholesteryl ester, CEH: Cholesteryl ester, CES: Carboxylesterase, CNS: Central 
Nervous System, CNV: Copy Number Variation, CYP: Cytochrome P450, CYP2D6: Cytochrome 
P450 2D6, CYP3A4: Cytochrome P450 3A4, FACoAH: Fatty Acyl CoA, hCES1: Human 
Carboxylesterase 1, hCES2: Human Carboxylesterase 2, hCES3: Human Carboxylesterase 3, KD: 
knock down, SLC transporters: Solute-Carrier Transporters, SNP: Single Nucleotide 
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Introduction  
People being treated for the same disease with the same drug will often experience different 
responses. The response can vary widely, from no response to a satisfying therapeutic response, 
from no adverse drug effects to fatal poisoning and all in between. It is therefore important to 
customize treatments in order for it to match specific individuals. This is personalized medicine.    
All types of medical treatments are to some degree personalized because they are administered 
following the clinical criteria. This criterion focuses on physiologic properties such as age, gender, 
weight and clinical manifestations including symptom severity, which plays a role in determining 
dose and medicine type. Administrating medication by following the clinical criteria increases the 
number of patients with a therapeutic response and limits the number of patients experiencing 
adverse effects. However, further personalization of medication is still necessary to improve the 
responses and efficacy. Besides the clinical criteria, genetic variation contributes to the response 
variations. Advancements in technology provide the opportunity to consider the genetic variations 
that affect drug responses. In addition, it might be possible to find biomarkers that can reveal these 
variations in patients allowing medical treatments to be further personalized. 
This project aims to contribute to the further personalization of medical treatments by looking at 
pharmacokinetics and identifying biomarkers for the activity of the drug metabolizing enzyme 
human carboxylesterase 1 (hCES1). hCES1 does not metabolize a lot of different drugs, but the 
drugs it does metabolize are commonly used. The adverse effects patients experience when using 
hCES1 metabolized drugs are not severe, but the patients often use the drugs for long periods of 
time, and experience a lowered quality of life than patients that are processing the drug at a normal 
rate. This study will investigate the metabolism of hCES1 and compare it to the well-researched 
metabolic mechanisms of cytochrome P450 (CYP) enzymes. Since hCES1 is not fully investigated, 
CYP 3A4 and 2D6 are used as models to enlighten the properties of hCES1. Furthermore, a simple 
in silico docking experiment is carried out, as a supplement, testing the affinity of cholesterol, 27-
hydroxycholesterol and methylphenidate to hCES1. This is done to try and develop a method for 
selecting compounds interesting for in vitro and in vivo testing. 
Personalized medicine, also known as individualized medicine, is an evolving medical field that 
aims to customize medical treatments through an individual's genetic profile. This method will 
assist to navigate medical decisions concerning diagnosis, prevention and treatment (Collins, 2014). 
Contrary to trial and error approach of certain conventional therapies, the goal of personalized 
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medical treatments is a more accurate match of drugs to patients, by giving the right treatments to 
the right patients at the right time. Individualizing the medication dose and treatment, can help 
prevent adverse drug response (ADR) and improve the therapeutic response. With multiple 
technologies such as genotyping, more accurate medical diagnostics and proteomics along with 
advances in medical genetics and sequencing of the human genome, personalization of medical 
treatments is obtainable (KK, 2009).  Medicine targeting have already shown progress in the field 
of cancer. DNA methylation in cancer cells (Momparler and Bovenzi, 2000) and pro-drugs that are 
capable of inducing apoptosis in specific cells by cell cleavage mechanisms (Denmeade et al., 
2012;Piccioni and Nguyen, 2014) are all a step in the right direction to take personalized medicine 
to a new level. 
Key Issue 
What causes the individual variation in hCES1’s activity, and which biomarkers can be used as a 
proxy for hCES1 activity? 
Objective: 
Investigation of the causes of individual variation in the hCES1 activity, and identification of easily 
measurable and accessible biomarkers, in blood, that can be used as a proxy for determining the 
hCES1 activity. 
Methods 
We completed a literature review with the aim to collect information on pharmacokinetics -and 
dynamics, CYP genes with focus on genotypes 2D6 and 3A4 and carboxylesterases more specific 
human carboxylesterase 1. Scientific textbooks and browsers such as Google Scholar and PubMed 
were used to gather information. Additionally, we used public information websites to find statistics 
concerning personalized treatment. SwissPdbViewer is used to visualize protein structure. Enzymes 
are depicted as monomers, even though some of them will make a trimer when interacting with a 
substrate. This is only to simplify the illustration. SwissDock was used for different docking 
analyses in order to study the affinity of endogenous inhibitors and xenobiotic substrates. 
Additionally it was used to formulate a theory distinguishing the above mentioned in the search for 
a hCES1 biomarker. The .pdb file 4AB1 was dock prepped using Chimera and the results from the 
different docking analyses were downloaded using the Chimera ViewDock tool.  
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Theoretical 
Personalized Medicine 
Personalization of all medical treatments is achieved by following the clinical criteria based on the 
physiologic traits of the patient. Further personalization of medical treatments beyond the 
physiology, the clinical criteria makes it possible for pharmaceutical companies to create new 
medicaments that are more effective and has fewer adverse effects. 
The term "genomic medicine" (precision medicine) suggests that by sequencing the human genome, 
the practice of medicine has been given the opportunity to enter a new era in which an individual 
patient's genome can contribute to identify the most favorable approach to care, whether it is 
diagnostic, preventive or therapeutic. As other factors such as metabolomics and proteomic 
technologies are taken into consideration in personalized medicine, genomic medicine is not a 
sufficient synonym. Precision medicine has proven to be optimal for the integration of new 
biotechnologies into medicine, which improves the management of patients as well as the 
understanding of pathomechanism of diseases (KK, 2009). 
Today many available technologies can determine genetic polymorphisms such as single nucleotide 
polymorphisms (SNP) and copy number variations (CNV) in a genome with precision and high 
efficiency. This allows scientists to explore differences in the human genome and thereby come up 
with a better-developed hypothesis in which the human genomes as well as levels of endogenous 
substrates are taken into account. Furthermore, next-generation sequencing is considered applicable 
for direct diagnostics in the near future (Meldrum et al., 2011). Additionally it will allow 
individuals to better maintain their health on account of understanding their genetic profile.  
Biomarkers 
A biomarker is a measurable parameter that indicates the development of a disease or the presence 
of biological changes. An example is raised body temperature during a cold or cholesterol in 
determining a patient’s change of getting coronary or vascular diseases. Biomarkers can be drug-
related or disease related. Disease related biomarkers are used to depict something about the disease 
as well as the state of the disease by finding a biomarker that indicates, whether the disease 
proceeds or comes to a halt (Mikeska and Craig, 2014).  
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Drug-related biomarkers are used to predict the effects of a treatment and to examine how the drug 
is metabolized within the individual. Additionally it is often used to indicate changes in the 
metabolic processes (Mikeska and Craig, 2014). This project focusses on biomarkers, providing 
information of drug-metabolizing enzymes’ activity, a so-called drug-related biomarker. 
For both disease and drug-related biomarkers, there is a required evaluation process for the data, to 
establish the level of confidence in the biomarker the scientist needs to get it approved. First, a 
molecule, metabolite or drug that can be used as a biomarker is found. Then it is hypothesized how 
it can be used as a biomarker, for a certain mechanism/disease. When this hypothesis is made, 
several kinds of experiments using animal models are done. One of these is to detect if the 
biomarker is suitable and targets the right mechanism/disease and another is to confirm that the 
biomarker is not affected by any other mechanisms/diseases. Once this is done, the biomarker is 
used on human models. One to confirm the results from the above mentioned first animal model, 
and then another confirming the second above mentioned. When the biomarker is drug related it has 
to be linked to the drug(s) outcome with the same mechanism of action. At last the biomarkers’ 
effect is linked to the outcome for drugs with differing mechanisms (Peck, 2007;Yi et al., 2006) 
Pharmacokinetics and pharmacodynamics 
The same drug often results in different responses when given to different patients with the same 
disease. Patients are divided into four groups, according to their response:  
1. Therapeutic response and no ADR 
2. Therapeutic response and ADR 
3. No therapeutic response and ADR  
4. No therapeutic response and no ADR   
To understand why the same drug can result in different outcomes, it is essential to look at how the 
body processes drugs. There are two aspects to consider; pharmacokinetics and pharmacodynamics. 
Pharmacokinetics has to do with what the body does to the drug, whereas pharmacodynamics has to 
do with what drug does to the body. Both play a role in determining the response, meaning both 
therapeutic and adverse drug response.  
Pharmacokinetics 
Pharmacokinetics has four steps: Absorption, distribution, metabolism and excretion. As seen in 
Figure 1, the two middle steps, distribution and metabolism, occur simultaneously.  
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Figure 1: Illustration of the four steps in pharmacokinetics: absorption - where drugs are moved from where it is 
administrated into circulation, distribution - where drugs are dispersed to different body tissues, metabolism - where drugs 
are transformed to smaller metabolites and excretion - where drug metabolites are removed from the body.  
Absorption 
Drug absorption is the process in which the drug moves from where it is administrated, e.g. orally in 
the form of a tablet, and into circulation. Most routes of administration go through biological 
membranes in the body. Many drugs are absorbed by passive diffusion, either lipid diffusion or 
aqueous diffusion. Lipid soluble drugs are absorbed by lipid diffusion across the plasma membrane. 
Water-soluble drugs can be absorbed by aqueous diffusion through aquaporins in the plasma 
membrane. Aqueous diffusion can only take place when drug molecules are of a low molecular 
weight (Brenner and Stevens, 2009).  
Some drugs need a carrier protein to be absorbed. Active transport is a form of administration that 
both requires a carrier protein and energy produced by the hydrolysis of ATP. In facilitated 
diffusion only a carrier protein is needed, no energy (Brenner and Stevens, 2009).  
Membrane transporter systems function as gatekeepers that either enhance or inhibit the transport of 
drugs across the membrane. The membrane transporters can be divided into two groups; influx and 
efflux transporters. Influx transporters facilitate the uptake of drugs through membrane barriers, 
where efflux transporters inhibits drug passing through the membrane (Girardin, 2006). 
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The process of absorption is irrelevant with topically administrated drugs, where drugs are directly 
administrated on the target tissue, and intravenously administrated drugs, where drugs are 
administrated directly into the blood stream (Brenner and Stevens, 2009).  
Distribution 
After the drug is absorbed, it is distributed to the body’s tissues. Distribution can happen through 
lipid diffusion if the drug is sufficiently lipid soluble or through active transport. The distribution 
depends on various parameters such as molecular size, lipid solubility and perfusion, which is the 
movement of blood through the system with exchange of oxygen and solutes. The distribution rate 
is faster in areas of the body that are highly perfused, such as the brain, heart, liver and kidneys. 
Molecular size and lipid solubility affect the distribution rate because these affect the distribution in 
different tissues (Brenner and Stevens, 2009). 
Transport proteins can affect the distribution rate by moving endogenous substances or drugs across 
biological membranes. They can be divided into two groups: the ATP-binding cassette transporters 
(ABC transporters) and solute-carrier transporters (SLC transporters). ABC transporters use the 
hydrolysis of ATP to drive the transportation of substances while the SLC transporters move ions 
and organic substances across biological membranes. Additionally, SLC transporters play an 
important role in the transport of several drugs. 
Metabolism 
As drugs are distributed through the circulatory system, they are continuously metabolized. The 
first breakdown of exogenous compounds happens in the small intestines, though the majority of 
metabolism occurs in the liver. Approximately 73% of the 200 most frequently used drugs in USA 
in 2002 were metabolized by the liver and the liver detoxification pathways (Guengerich, 
2008;Williams et al., 2004). Drugs are broken down by both human carboxylesterase 1 (hCES1) 
and human carboxylesterase 2 (hCES2) in the intestine (Imai et al., 2006) but the hydrolase activity 
is mainly provided by hCES2. hCES1 contributes with some hydrolase activity too, however, the 
main role of hCES1 in drug metabolism is in the liver (Imai et al., 2006;Satoh et al., 2002). 
Cytochrome P450 3A4 (CYP 3A4) is also found in the intestine (Kolars et al., 1992;Watkins et al., 
1987) and contributes significantly to the first-pass metabolism of a couple of intestinally dosed 
drugs (Kolars et al., 1991;Paine et al., 1996). 
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Through the liver detoxification pathways, both endogenous substances such as hormones and 
xenobiotics such as drugs are eliminated. These detoxification pathways consist of enzymatic 
processes, which inactivate the compounds and make them more hydrophilic, and they are thereby 
easily excreted from the body. The process of making the compounds more hydrophilic happen in 
two ways, phase I- and phase II-reactions. Additionally metabolism of compounds undergoes either 
phase I-, phase II-reactions or both, as illustrated in Figure 2 
 
Figure 2: Illustration of phase I and phase II drug metabolism. Xenobiotic compounds are destined to be inactivated and 
broken down by undergoing either phase I and/or phase II reactions. These metabolic reactions are catalyzed by a variety of 
enzymes that are primarily expressed in the liver. Modified from (Grant, 1991).  
In phase I-reactions, the substrates are oxidized, resulting in either a newly formed polar functional 
group or the exposure of an already existing polar functional group. Frequently the polar group 
added is a hydroxyl- or an epoxy group, which often is enough to inactivate the compound and by 
that allows it to be excreted. Phase I drug-metabolizing enzymes hydrolyze various ester-containing 
drugs and pro-drugs such as anti-tumor drugs (capecitabin and CPT-11), narcotics and angiotensin-
converting enzyme (ACE) inhibitors (cilazapril, quinapril, temocapril and imi- dapril) (Satoh and 
Hosokawa, 2010). Most phase I-reactions are catalysed by the cytochrome P450 (CYP) enzymes, 
which are located in the endoplasmic reticulum of the hepatocytes (Borup, 2010;Grant, 1991).  
Another drug metabolizing enzyme family is the carboxylesterases (CESs). Tissue expression 
profiles of CESs show that the highest activity levels are found in the mammalian liver microsomes 
(Satoh and Hosokawa, 2010). 
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In phase II-reactions, the compounds conjugate with a hydrophilic group which radically changes 
the structure, hence completely loses its actual function. The phase II-reactions are performed by 
various substrate specific enzymes, and take place in the cytosol, mitochondria and in the 
endoplasmic reticulum (Borup, 2010). 
Excretion 
Drug excretion is the removal of the drug from the body. This happens primarily through the urine 
but excretion can also happen through feces, bile, sweat, tears, breast milk, saliva, and through 
exhalation. When a drug is excreted through the urine, it is filtered in the glomeruli in the kidneys. 
Some drugs can be reabsorbed, depending on its lipid solubility. Reabsorption increases with an 
increasing lipid solubility and decreases when drugs are transformed into polar metabolites during 
metabolism. The body cannot excrete drugs that have a high molecular weight nor polar and 
nonpolar groups through the urine as these drugs only are excreted through the bile. 
Fast metabolizers and slow metabolizers 
When patients experience different adverse effects as response to the same drug, it may be caused 
by different variations in genes coding for drug-metabolizing enzymes. Polymorphisms in genes 
can cause increased, decreased or absent enzyme expression (Meyer and Zanger, 1997). Since the 
CYP enzymes metabolize over 70%, and esterase enzymes metabolize about 10% of the 200 most 
frequently used drugs in USA in 2002 (Williams et al., 2004), polymorphisms in the genes coding 
for these have a great impact on a patient’s drug metabolism. 
A small-scale variation is SNPs where a single nucleotide differs. If SNPs are located in DNA 
coding for a drug-metabolizing enzyme it might change the function of the enzyme. Another type of 
genetic variation is structural variation, where more base pairs are involved. A large subgroup in 
structural variations is CNVs, which include insertions, deletions and duplications. If a patient has a 
genetic variant in which the gene for a drug-metabolizing enzyme is duplicated, it will result in a 
faster metabolism of the drug than average and the patient therefore needs a higher dose than other 
patients in order to get a therapeutic response. On the other hand, patients with deletions or non-
conservative mutations in genes coding for drug metabolizing enzymes have a slower or 
nonfunctional metabolism, and thereby a higher concentration of the drug in the blood. These 
patients will be at a higher risk of experiencing adverse effects. 
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This project focusses on metabolism as the primary factor in pharmacokinetics, based on the 
assumption that the metabolism, more specific the activity of drug metabolizing enzymes, is the 
primary factor in drug concentration. This assumption is based on the fact, that the activity of drug 
metabolizing enzymes has a direct impact on the drug concentration in the blood. Absorption, 
distribution and excretion also influence the concentration of drug exposure in the body but 
variations in these systems are based on the chemical composition of the medication. In order to 
personalize treatments based on the variations in absorption, distribution and excretion, new types 
of medication has to be defined and developed. It is assumed that the medications available today is 
effectively absorbed, distributed or excreted by most patients, and that there is an alternative to 
those who cannot. This makes the variations in these three factors less relevant when looking at the 
specific drug concentration in a patient.   
Pharmacodynamics 
Pharmacodynamics is a field of medical and molecular biology, which explains what certain drugs 
do to the body. Due to the fact that different drugs affect the body in the same intended way, a 
method is needed to compare the intended effects and adverse effects a drug have in a patient. This 
is done by comparing the effectiveness of different drugs, including exposure as well as the 
intensity of therapeutic effects and adverse effects (DiPiro and Sprull, 2010).   
The factors influencing the efficiency of a drug varies in humans due to genetic variations that 
affect the individual response. This could be a higher receptor density on the cell surface, which 
leads to an individual with a higher responsiveness. Furthermore, if genetic variations lead to an 
alteration in the conformation of the receptor and thereby lowers the affinity for a drug it may lead 
to altered pharmacodynamics. Genetic variations and all the factors that affect the drug’s effect on 
the site of action will be an alteration in pharmacodynamics (Meyer and Zanger, 1997). 
Methods for choosing the right drug to treat a patient do not consider effect duration, exposure 
effectiveness or the adverse effects the drug can lead to over time; it is only a valid method for 
preliminary differentiation between drugs (DiPiro and Sprull, 2010).  
Combining pharmacokinetics and pharmacodynamics to personalize medical treatments 
To investigate why patients experience different responses to the same dose of the same drug, 
metabolism and receptor affinity has to be considered. The metabolism, as mentioned earlier, 
affects the exposure a certain drug in the system and the concentration of that drug during exposure. 
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The receptor affinity influences the concentration needed to achieve the intended therapeutic effect. 
This project combines metabolism and receptor affinity in four new patient groups, defined in this 
project as the patient’s turnover profile: 
1. Fast metabolizer and high receptor affinity: The easiest to medicate because the high 
receptor affinity makes up for the fast metabolism. 
2. Fast metabolizer and low receptor affinity: Has the highest chance of being over-medicated, 
as the fast metabolism will lead to a low drug concentration in the blood while the receptors 
cannot use the drug efficiently. 
3. Slow metabolizer and high receptor affinity: Easy to treat, as the drug concentration does 
not have to be high. 
4. Slow metabolizer and low receptor affinity: Has an increased chance of being over-
medicated, as this person will require a high drug concentration to achieve the wanted effect. 
The outcome of the turnover profiles mentioned above are all based on the previous theory and on 
“normal” medicaments, not pro-drugs. It will be possible to prevent over-medication of a patient if 
the metabolism can be determined before treating them. For example, if the metabolism of a patient 
with turnover profile number three can be determined before treating the patient, one knows that the 
patient will have a higher concentration in a longer exposure period than a patient with turnover 
profile number one. This will lead to a treatment where the dose will be lowered from the start.  
The therapeutic window 
When considering personalization of treatments in which patients experience different responses, a 
better understanding of a patient’s individual metabolism can help find the best fitting dose. This 
will ensure the best possible therapeutic response and fewest possible adverse effects.  
Adverse effects can be dose-dependent or non-dose-dependent. Non-dose-dependent adverse effects 
are not relevant when focusing on metabolism as they are independent of metabolism and often 
occur due to allergies to the drug or metabolites of the drug. Since the focus of this project is on 
metabolism, the dose-dependent adverse effects are of interest.  
The therapeutic window is the difference between the therapeutic dose and the toxic dose. The best 
response is acquired if the actual drug dose is between these two thresholds, as seen in Figure 3. If 
the therapeutic window is narrow it is imperative to find the correct dose, as a slight increase in 
dose can be enough to cause adverse effects and a slight decrease in dose will result in loss of 
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therapeutic response. If the therapeutic window is wider, a therapeutic effect without adverse effects 
is obtainable with a less precise dose. Personalized medicine focusses on drugs that have a narrow 
therapeutic window.  
 
Figure 3: Therapeutic Window: The curve illustrates the plasma concentration over time.  The redline indicate the plasma 
concentration level where it becomes toxic, and the green line represent the theraputic dose. 
As with adverse effects, the therapeutic response can also be dose-dependent. If patients are treated 
with a drug in which both the therapeutic response and adverse effects are dose-dependent, patients 
receiving a higher dose will have a better therapeutic effect but also be at higher risk of adverse 
effects.  
Cytochrome P450 enzymes and their properties 
To study the pharmacokinetic changes resulting in an altered efficiency of hCES1 metabolism, it is 
necessary to look at CYP enzymes and compare the two distinct regulation mechanisms. An 
understanding of the term etiology is necessary in this context. Etiology is the study of the causation 
or origin of a disease. The definition of etiology used today arose when smoking was shown to 
cause cancer. It can be used to determine diseases and even to distinguish between different 
diagnoses (Green, 2007;Oxford, 2014). This ability to distinguish between diseases by using 
biomarkers opens up the opportunity to use the right treatment on the right individual. As 
mentioned above the focus will be on the metabolism of drugs. The metabolism of medicaments is 
an already investigated field. Six CYP enzymes play a crucial role in the metabolism of drugs; 
CYP1A2, 2A6, 2C8, 2C9, 2D6 and 3A4. These account for about 75% of drug metabolism in the 
liver (Guengerich, 2008). As seen in Figure 4, CYP enzymes are structurally very similar but there 
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are some differences in the active site, the conformational change when interacting with substrates 
and in their F’ and G’ domains (Guengerich, 2008). 
 
Figure 4: Illustration of two important CYP enzymes. The yellow or orange areas are the N-terminal domain, the light purple or dark purple 
areas are the C-terminal domain. The green colored areas are the F-helix domains, and the blue colored areas are the G-helix domains. The 
red colored molecule in the middle of the individual enzyme is the heme group (de Groot et al., 1999;Ekroos and Sjogren, 2006;Lewis, 
2002;Lewis, 2003;Raunio and Rahnasto-Rilla, 2012;Scott and Halpert, 2005;Williams et al., 2004)]. The illustration is based on .pdb files 
2F9Q (CYP2D6) and 1TQN (CYP3A4) from RSCB.org. 
As with many other genes, the CYP genes are found in various isoforms in the population. These 
genetic variations give rise to different metabolizing phenotypes, which becomes apparent when 
using biomarkers in activity assessments.  
The important role of metabolism and receptors culminating in what this report refers to as a 
“turnover profile” and other important factors are discussed in the earlier section; Combining 
pharmacokinetics and pharmacodynamics to personalize medical treatment. In this part of the 
project, these factors are not accounted for as CYP enzymes make up 75% of liver metabolism. 
Many substrates, which are useful in estimating the activity of a particular CYP enzyme, have been 
identified for the CYP enzymes 3A4, 1A2, 2C9, 2D6 and 2C19, as well as inhibitors and inducers, 
see Table 1 (Guengerich, 2008). The focus will be on the well-studied CYP enzymes CYP2D6 
(2D6) and CYP3A4 (3A4). Tabel 1 clearly indicate that 2D6 have a variety of substrates that cause 
inhibition of the enzyme, whereas 3A4 was shown to have fewer inhibitors, but exist in different 
forms that changes the properties of the enzyme (Guengerich, 2008). The difference between the 
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2D6 and 3A4 inhibition potential is due to the difference in their complex regulatory mechanisms 
that will be explored in the next two sections. 
Table 1: Metabolism of 2D6 and 3A4-mediated inhibitors, substrates, and inducers. The binding/inhibition is shown by the 
pink and red marks, whereas the latter shows the strongest binding.  3A found in several forms changes the properties and 
thereby its inhibitors it reacts with. Modified from (Spaggiari et al., 2014). 
 
Together the CYP enzymes 2D6 and 3A4 make up 90 % of the CYP enzyme metabolism of drugs 
used in 2002 (Guengerich, 2008). These are used in this project to explain the use of biomarkers 
and to explain why hCES1 could be used in the personalization of medicine. The CYP enzymes are 
well investigated and well understood; hence the properties can be transferred or linked to hCES1.  
CYP2D6 
2D6 is one of the key enzymes used in the degradation of xenobiotics and the 2D6 gene is part of 
the CYP2 family that all have 9 exons and 8 introns (Guengerich and Cheng, 2011;Wang et al., 
2009), consisting of an open reading frame of 1491 base pairs (Wang et al., 2009). Most of the other 
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CYP genes are found in clusters on different chromosomes. The 2D6 gene is the only gene which 
leads to a functional enzyme when found alone. This could explain the importance of having a 
functioning 2D6 enzyme present (Nelson et al., 2004). 2D6 is produced in the liver and is 
responsible for about 10-25% of the drug metabolism (Williams et al., 2004;Zhou, 2009). 2D6 is 
subject to CNV, where duplications increase the activity and deletions decrease or cause complete 
loss of activity (Zanger and Schwab, 2013).  
The 2D6 phenotype can often be determined clinically by using the substrate debrisoquine (Llerena 
et al., 2009). Substrates, products and proteins may alter the activity due to changes in the structure. 
These can be used as biomarkers to determine which turn over profile the patient belongs to (Zanger 
and Hofmann, 2008). A strong inhibitor causes, as minimum, a 5-fold increase in the plasma 
concentration area under the Curve (AUC)-values while a moderate inhibitor causes at minimum a 
2-fold increase. A weak inhibitor causes less than a 2-fold increase (Zhou, 2009) 
Using a cocktail approach scientists have found that 2D6 react to various molecules that are 
naturally found in vivo, mostly from the diet (Spaggiari et al., 2014). Substrates and inhibitors that 
interact with 2D6 and their effect on 2D6 activity are shown in Table 1. Inducers of 2D6 are still to 
be discovered as the only evidence of alteration inducing 2D6 activity comes from gene 
polymorphisms and not alterations of the transcript protein (Wang et al., 2009). 
Variations in 2D6 that have shown to increase or decrease enzyme activity are found in mice as 
well as in humans. There are at least 74 different 2D6 alleles (Wang et al., 2009), the most severe 
and common variations are shown in Table 2. Decreases in 2D6 activity is not severe to the enzyme 
activity and have a small impact on the patient, but null alleles cause a total loss of function and are 
also often observed in vivo. As seen in Table 2, the most frequent null allele in the western world is 
2D6*4 at a frequency of 0.15-0.25. Null alleles cause no enzyme activity and this can result in 
severe adverse drug response (ADR) (Zanger and Schwab, 2013).  
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Table 2: Illustration of the different outcomes of different 2D6 alleles. The Various alleles of 2D6, key mutation number, 
Protein effect, functional effect, frequencies and clinical correlations, are all illustrated in figure. The folding of proteins 
effect the activity of the enzyme while a null allele causes a loss of gene function leading to a risk of ADR that results in 
toxication in some patient, while only a decrease would cause no toxication.  Abbreviation: Ethnicities_ AA, African 
American; Af African; As Asian; Ar, Arab; Ca Caucasian; Hs, Hispanic; In, Indian; Pc, Pacific; SA, South American; 
gMAF, Global allele frequency. Rs number: accession number used by researchers and databases to refer to specific SNPs. 
Also called Reference SNP cluster ID. Modified after (Zanger and Schwab, 2013).  
 
Furthermore, the expression of metabolic enzymes have shown to be controlled by interleukin (IL)-
1β, TNF-α and IL-6. In the presence of cancer or just inflammation crucial down regulation of the 
metabolizing enzymes is seen (Aitken et al., 2006). 
The 3D structure of 2D6 
2D6 has an active site within the catalytic pocket, which is associated with a heme group.  In the 
catalytic pocket, many crucial residues recognize substrates, bind the substrate and control the 
transport of electrons. The most important residues are ASP301, HLU216 PHE483 and PHE120. 
The crystal structure suggests that the PHE120 might control the orientation of the aromatic ring 
found in most substrates. The aromatic ring within the substrate needs to bind in respect to the heme 
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group. The heme group can react with a planar aromatic ring, and protonated basic nitrogens 
through oxidation (Rowland et al., 2006). 
CYP3A4  
3A4 is the most abundant enzyme in the liver (Hayes et al., 2014) and is a part of the human CYP 
subfamily 3A which consists of 3A4, 3A43, 3A5 and 3A7 (Westlind et al., 2001). The 3A4 gene 
resides on chromosome 7q21.1 (Zanger and Schwab, 2013). Multiple signaling pathways regulate 
3A4. The activity is continuously regulated at a transcriptional level by the C/EBPα,C/EBPβ (Jover 
et al., 2002;Rodríguez-Antona et al., 2003) and HNF4α (Tirona et al., 2003) as a negative and 
positive regulator, respectively. Regulation of 3A4 is not only seen on transcriptional level, several 
overlapping substrate binding domains and allosteric regulation of the enzyme activity have been 
detected too (Roberts et al., 2011).  
 
3A4 is a membrane protein which metabolized about one third of most of the drugs on the US 
market in 2002. Furthermore it metabolizes many endogenous and exogenous substrates (Denisov 
et al., 2007;Fujiwara and Itoh, 2014;Guengerich, 1999;Hayes et al., 2014;Williams et al., 2004). 
The CYP enzymes’ domains and active sites are very similar, but there are some differences. The 
structure of 3A4 folds in a characteristic CYP way with a small N-terminal domain mainly 
consisting of β-strands and a larger helical C-terminal domain, which holds the heme group and the 
heme ligating CYS442, see Figure 5A. The active sites (MET114, SER119, ARG212, ILE301, 
PHE304, ALA305, THR309, ALA370, LEU373 and LEU479) and additional active sites 
(VAL101. ASN104, ARG105, ASP214, PHE215, ASP217, PRO218, GLU374 and SER478) 
resides in the N-terminal and C-terminal domains. The additional active sites interact when 3A4 
interacts with for example erythromycin. The large quantity of active sites result in a large active 
site area in 3A4 (Szklarz and Halpert, 1997;Williams et al., 2004). Furthermore, 3A4 is very 
flexible and undergoes large conformational changes when interacting with specific substrates. 
These conformational changes happen at both the active sites and in structures further away from 
the active sites, see Figure 5B (Ekroos and Sjogren, 2006;Williams et al., 2004). 3A4 have a highly 
flexible catalytic pocket, when compared to 2D6. The catalytic pocket can be altered to change the 
affinity for different substrates. This affinity does ultimately end up in a regulation of the enzyme. 
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Figure 5: 3A4 complexes illustrating the conformational changes 3A4 undergoes when interacting with the inhibitor 
ritonavir. The inhibitor is colored black. The light pink and pink area is the C-terminal domain, and the light yellow and 
yellow area is the N-terminal domain. The light blue and blue area is the F helix domain. Dark red regions ribbons and side 
chains are areas that interact with the heme group. The brown and light brown molecule is the cysteine group which ligates 
the heme group. The orange regions and side chains are the primary active sites, and the dark orange regions and side chains 
are the additional active sites (Scott and Halpert, 2005;Szklarz and Halpert, 1997;Williams et al., 2004). The figure is based 
on the .pdb files 3NXU (ritonavir) and 1TQN (3A4 with no substrates), downloaded from RCSB.org.  
The ability to change conformation makes 3A4 able to fit both large and small substrates into its 
active site area and this flexibility makes it suitable for the metabolism of a larger group of drugs 
(Ekroos and Sjogren, 2006;Williams et al., 2004).  This provides a reason for why 3A4 makes up 
the largest part of the CYP enzyme metabolism but the relationship between structure, 
conformational changes and drug metabolism is not yet fully understood (Hutchinson et al., 
2004;Yano et al., 2004). 
Evidence shows that in some cases CYP3A5 and 2D6 interact with 3A4 to break down drugs. 
Additionally it is only possible to determine the relative specificity of 3A4 and 3A5 by using 
individual recombinant human CYP’s (Hutchinson et al., 2004;Yano et al., 2004). This suggests 
that they affect each other more than science has shown to this day.  
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A number of different substrates have been proposed as being capable of estimating 3A4’s 
interaction with different drugs. Furthermore it has been estimated that it is better to use several 
probes representing different substrate groups for the in vitro assessment of 3A4 drug interactions 
(Guengerich, 2008;Kenworthy et al., 1999). Testosterone has been used as a biomarker for the 
activity of 3A4 in vitro because the enzyme metabolizes testosterone to 6-β-hydroxy testosterone 
(Iwahori et al., 2003). At least two different substrates are known to be applicable to measure 3A4 
activity in vivo. The first substrate useful in measuring the activity is 6-β-hydroxycortisol, which 
has been used in a number of studies. It is useful as it is a natural nonspecific marker of 3A4 found 
in a person’s urine (Bienvenu et al., 1991;Ged et al., 1989;Kovacs et al., 1998;Roby et al., 
2000;Saenger, 1983). When broken down by 3A4, 3-hydroxyquinidine is a quinidine metabolite. 
This was proposed as a new biomarker for 3A4 activity and was compared with 6-β-
hydroxycortisol. The result showed that 6-β-hydroxycortisol had some limitations and that 3-
hydroxyquinidine, measurable in both plasma and urine, therefore might be a better biomarker for 
3A4 activity (Damkier and Brøsen, 2000). 3A4 is not only important for the metabolism of 
xenobiotic but is also an efficient steroid hydroxylase. It is involved in the catabolism of 
endogenous steroids (Zanger and Schwab, 2013). These steroids are listed in Table 3. These 
steroids can be used as a proxy for the 3A4 activity. Testosterone is one example of a biomarker 
that has been used as a probe. As seen in Table 3 there is a variety of probes, but testosterone and 
cortisol are the only endogenous substrates (Fuhr et al., 2007). 
 
Table 3: Endogenous substrates and probes: The table shows which common known endogenous substrates are catalyzed by 
CYP3A4. Further it is seen that only two of the probes are endogenous substrates. Even though more probes can be found, 
these are examples. 
Endogenous substrate Source Probes Source 
Bile acids (Zanger and 
Schwab, 2013) 
Midazolam (Patki et al., 2003) 
Testosterone (Zanger and 
Schwab, 2013) 
Triazolam (Patki et al., 2003) 
Progesterone (Zanger and 
Schwab, 2013) 
Alprazolam  (Hirota et al., 2001;Williams et al., 2002) 
  
Androstenedione (Zanger and 
Schwab, 2013) 
Dextromethorphan (Fuhr et al., 2007) 
Cortisol (Zanger and 
Schwab, 2013) 
Erythromycin   (Baker et al., 2004) 
4β-hydroxycholesterol (Diczfalusy et 
al., 2001)  
Alfentanil (Klees et al., 2005) 
  Testosterone  (Kamdem et al., 2004) 
  Cortisol (Huang et al., 2004) 
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CYP2D6 and 3A4 as models 
There are similarities in the structure of 3A4 and 2D6. The differences in these enzymes are in their 
mode of function, regulation and frequency of polymorphisms. 2D6 have not shown to have 
inducers on a substrate level. However, at gene level, different CNV’s causes an increase or 
decrease in activity. 2D6 have also shown to have various polymorphisms that alter the activity, see 
Table 4.  
Unlike 3A4, there is no observation of post-translational 2D6 activity regulation. Two variants of 
the 3A4 gene are found, but none of these variants shows a significant alteration in enzyme activity. 
However, one variant has been suggested to lead to an increased risk of prostate cancer (Zanger and 
Schwab, 2013). In contrast to 2D6, the binding of inhibitors or inducers regulates 3A4 activity. This 
is due to allosteric alteration of the active sites (Williams et al., 2004). As the enzyme activity does 
not change significantly in different genomic variants, the only regulatory complexes that would 
explain the difference in enzyme activity are ligand-binding and allosteric modulation. In Table 4 
below the inducers and inhibitors for 3A4 and 2D6 are shown as a comparison of the two CYP 
genes (Zanger and Schwab, 2013). 2D6 do not have any inducers but many inhibitors have been 
discovered. Nevertheless, almost twice the inducers than inhibitors are found for 3A4. The 
difference in the number of inducers and inhibitors confirms that 3A4 is flexible at modulatory 
level, whereas 2D6 only is inhibited. These features make the genotyping of 2D6 possible while 
3A4 activity only can be accounted for by the actual regulation at the given time. 
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Table 4: A combination of inhibitors of 2D6 and inducers as well as inhibitors of 3A4. 2D6 has a high amount of inhibtiors 
that affect the enzyme activity. 3A4 also has a high amount of inhibitors, but twice as many inducers. 2D6 can thereby only be 
inhibited by substrate interaction while 3A4 can be induced or inhbited by substrate interaction. Modified from (Zanger and 
Schwab, 2013) 
 
 
Table 4 shows that there is a significant difference in the post-translational regulation and as earlier 
mentioned, the catalytic pocket of 3A4 have multiple substrate binding sites that overlap as well as 
allosteric interaction, which can be transferred to the interaction between hCES1 and 
inhibitors/inducers. Furthermore, 2D6’s genotypic importance can be transferred to the CNV of 
hCES1 and explains, to some extent, the importance of CNV’s. 
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The combination of the properties mentioned above is thought to regulate the activity of hCES1. As 
genotyping of 3A4 cannot explain activity alterations, it is possible to apply the use of probes in 
3A4 to using hCES1 activity probes. This could be an excellent method for determining the 
phenotype of hCES1 if genotyping is not a possibility. 
Metabolomics 
Metabolome is a term referring to the complete set of small-molecule chemicals within a biological 
sample. The interactions between gene expression, protein expression and the cellular environment 
are responsible for the identities, concentrations and moving of metabolites. Metabolomics focuses 
on a broad series of metabolites instead of focusing on a single metabolite, which is the approach 
often used in biochemistry. Metabolomics combine quantitative data on several metabolites to get a 
better understanding of mechanisms involving multiple metabolites, such as metabolic dynamics 
associated with disease and drug exposure. Metabolomics can be used to understand diseases and 
medicaments’ impact on the body as these affect the body’s metabolome. Changes in the 
metabolome as a result of the disease or medicament is known as long-term changes in the 
metabolome.  
Analysis of the changes in the metabolome can result in an initial metabolomic signature (novel 
biomarker). Further investigation of the initial metabolic signature could potentially lead to the 
discovery of a biomarker for the disease or drug. This means that by applying metabolomics to the 
previous information and the following information about hCES1, a possible initial metabolomic 
signature for hCES1 activity can be proposed (Quinones and Kaddurah-Daouk, 2009). 
Carboxylesterases and their activity  
Carboxylesterases (CESs) are found in several organisms including mammals. They are a multigene 
enzyme family, part of the serine hydrolase superfamily (Williams et al., 2011). These enzymes are 
engaged in the metabolic activation or detoxification of xenobiotics, such as drugs, pesticides and 
other environmental toxicants. In addition, they effectively catalyze the hydrolysis of various 
amide- and ester bond-containing chemicals, as well as the hydrolysis of chemicals and drugs to 
their respective free acids. CES’s are thought to be one of the main determinants of 
pharmacokinetics of ester drugs and pro-drugs (Satoh and Hosokawa, 2010). 
The catalytic triad of amino acids at the CES active site is vital for catalytic activity. At the base of 
the active site, nucleophilic serine residue is found which attacks the carbonyl carbon of ester-
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containing substrates (Ross et al., 2010). The mRNA expression of hCES1 and hCES2 is greatest in 
the liver, which suggests a significant role in the metabolic detoxification of xenobiotics. 
Furthermore, CESs are expressed in the stomach, kidney, heart, spleen, testis and colon (Williams 
et al., 2011). The expression of hCES1 greatly exceeds hCES2 in the liver (about 50-fold), but 
hCES2 is highly expressed in the intestine (Laizure et al., 2013).  
Though carboxylesterase-mediated hydrolysis is commonly overlooked at the clinical level, it plays 
a significant role in the metabolism of various therapeutic agents, prescribed widely. These drugs 
from varied classes include angiotensin-converting enzyme inhibitors (ACEIs), 3-hydroxy-3-
methylglutaryl coenzyme A inhibitors (statins), antiviral agents, antiplatelet drugs, narcotic 
analgesics, angiotensin receptor blockers (ARBs), immunosuppressants, central nervous system 
(CNS) stimulants and oncology agents. The increasing awareness that diseases, genetic factors and 
drug interactions alter the enzyme activity of these enzymes and have a significant impact on the 
therapeutic effects of substrate drugs is due to the increasing number of therapeutic agents, subject 
to carboxylesterase hydrolysis. However, even though we understand how CYP enzymes in 
disposition and furthermore the clinical effects of several drugs are important, in the metabolism of 
substrate drug, the role of carboxylesterase hydrolysis has been broadly understudied (Laizure et al., 
2013). 
Based on genomic structure and genetic sequence, a recent genomic analysis determined five 
different CESs subfamilies within the mammalian family, yet the far most well studied are the 
proteins of subfamily CES1 and CES2. Mammalian CES substrates are endogenous (i.e., acyl-CoA 
esters and acyl-glycerols) as well as exogenous. To some extent, both CES1 and CES2 have 
imbricating substrate specificity and in a lesser degree, substrate selectivity too. For instance, a 
comparison between structures formed between hCES1, heroin, cocaine, 4-methylumbelliferyl 
acetate and 6-monoacetylmorphine and structures formed between hCES2 and the same substrates, 
showed that hCES1’s affinity was greater for cocaine while hCES2’s affinity was higher for 4-
methylumbelliferyl acetate and 6-monoacetylmorphine. The two enzymes showed similar Km value 
for heroin. This data propose that hCES1 prefers compounds containing a bigger acyl moiety while 
hCES2 preferentially hydrolyzes compounds containing a bigger alcohol moiety relative to the acyl 
component (Williams et al., 2011). CESs are considered imperative enzymes associated with pro-
drug activation, prominently with respect to up-regulation in tumor cells, tissue distribution and 
turnover rates, due to the phase I reactions described in; Metabolism  (Satoh and Hosokawa, 2010). 
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Drug Hydrolysis 
An ester is made up by an acyl- and an alcohol group. The result of an ester hydrolysis is the 
formation of the analogous carboxylic acid and alcohol and the product is usually more polar, 
compared to the original ester. CESs lack substrate specificity and even though drug substrates are 
vulnerable to carboxylesterase (CES) hydrolysis or hydrolysis by other esterases, one CES usually 
serves as the major hydrolysis pathway as that specific CES predominates with each substrate. 
Based on the ester structure, CES predominates can be predicted. The enzyme of hCES1 generally 
prefers esters with a large acyl group and small alcohol group while hCES2 prefers the opposite, a 
small acyl group and large alcohol group (Laizure et al., 2013). An ester group is often added into a 
drug’s structure during synthesis and design with the aim to improve oral absorption. Additionally 
passive transport through membranes is more effective as converting carboxylic acid into an ester 
increases hydrophobicity. Figure 6 illustrates, among others, the pro-drug oseltamivir’s hydrolysis 
into oseltamivir carboxylate, which illustrates the above mentioned.  
 
Figure 6: Hydrolysis pathways for hCES1 and hCES2. hCES1 hydrolyses esters with a large acyl group and a small alcohol 
group. hCES1 hydrolyses oseltamivir to oseltamivir carboxylate, leaving a -OH group, increasing the compounds 
hydrophobicity.  hCES2 hydrolyses compounds with a small acyl group and a large alcohol group. hCES2 hydrolyses 
presugrel into thiolactone (Laizure et al., 2013) 
Oseltamivir carboxylate, the active neuraminidase inhibitor, has poor oral bioavailability and is 
highly polar. The result of the carboxylic acid’s ethoxy ester is a compound with good 
bioavailability, which is less polar (He et al., 1999). After absorption, hCES1 in the liver quickly 
hydrolyses the ester to the active drug moiety resulting in an antiviral compound. This compound is 
a pro-drug and avoids the additional cost of intravenous administration, the inconvenience and is 
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orally active. The hydrolysis of methylphenidate to its analogous carboxylic acid, illustrated in 
Figure 6, shows that an ester functional group might be a significant structural factor for a 
therapeutic agents’ activity. The active compound, methylphenidate, is hydrolyzed to ritalinic acid, 
the inactive carboxylate, by hCES1 in the liver. Clopidogrel and aspirin, the broadly used 
antiplatelet drugs, are prominent examples of hydrolysis as an inactivation pathway (Laizure et al., 
2013). 
Substrates 
Regardless of the big number of broadly prescribed drugs subject to CES-mediated hydrolysis, the 
clinical importance of ester hydrolysis in drug metabolism might have been undervalued. 
Cardiovascular drugs including ARBs, statins, ACEIs, anticoagulants and fibric acids, is the major 
therapeutic class of CES substrate drugs. Three angiotensin receptor blockers (ARBs), olmesartan 
medoxomil, candesartan cilexetil and azilsartan medoxomil are pro-drugs that require hydrolysis to 
the active metabolite. A hCES2 catalyzing process in the small intestine that takes place during 
absorption. All ACEIs, except Lisinopril and captopril, are ester pro-drugs. They are hydrolyzed to 
their analogous therapeutically active carboxylic acid by hCES1. The three frequently used 
antiplatelet agents; clopidogrel, aspirin and prasugrel are all subject to CES hydrolysis. Clopidogrel 
needs to be metabolized to thiolactone (2-oxo-clopidogrel) as it is a pro-drug with no antiplatelet 
activity. Thiolactone is a transitional inactive metabolite that is later metabolized to the active form. 
CYP enzymes catalyze these two metabolic steps. hCES1 hydrolysis is competing with this 
activation pathway of both clopidogrel and the thiolactone metabolite causing metabolic products 
that are inactive. hCES2 hydrolyses aspirin to salicylic acid. Aspirin represents an inactivation 
pathway of its antiplatelet effect, as it is the active antiplatelet agent. However, hCES2 hydrolysis 
acts as an activation pathway for the anti-inflammatory activity of aspirin as salicylate is the main 
anti-inflammatory moiety. Prasugrel is a substrate pro-drug for hCES2. After oral administration, 
during absorption, hCES2 hydrolyses prasugrel to thiolactone. The CYP system then metabolizes 
the thiolactone to the active moiety. The result of this hCES2-mediated hydrolysis is the formation 
of the thiolactone metabolite. Due to the efficiency of this reaction, the plasma concentrations of 
prasugrel after oral administration are normally below detectable limits (Laizure et al., 2013)  
The new oral anticoagulant, called dabigatran, is hydrolyzed by hCES1 and possibly hCES2 at two 
separate sites in order to produce the active metabolite. Dabigatran is given as a double ester pro-
drug and is a reversible direct thrombin inhibitor (Blech et al., 2008). The two thiolactone statins, 
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simvastatin and lovastatin, as well as the two esters of fibric acids, fenofibrate and clofibrate are 
lipid-lowering agents and hCES1 substrate pro-drugs. Three therapeutic categories of CES 
substrates affecting the CNS exist: CNS stimulants, methylphenidate and cocaine; meperidine, 
opiate agonists and heroin; rufinamide (anticonvulsant drug). To understand the metabolism of the 
most extensively studied CES substrate, cocaine, plentiful animal, human and in vitro studies have 
been made. It is subject to both hCES1 and hCES2 hydrolysis at two separate ester sites on the 
cocaine structure. To produce benzoylecgonine, hCES1 catalyzes the hydrolysis of the methyl ester 
and to produce ecgonine methyl ester, hCES2 catalyzes the hydrolysis of the benzoyl ester. Both 
metabolites are inactive and is eliminated renally (Laizure et al., 2013).  As mentioned in Drug 
Hydrolysis, hCES1 hydrolyzes methylphenidate to ritalinic acid, a catalyzed hydrolysis that is 
stereo-selective (Zhu et al., 2010).  Administered as a racemate, methylphenidate consist of d- and 
l-methylphenidate. The less active l-isomer is of greater efficiency for hCES1 hydrolysis than the 
active d-isomer (Laizure et al., 2013). Heroin is hydrolyzed by hCES2 among other esterases to its 
monoacetylmorphine metabolite and later to morphine whereas meperidine is hydrolyzed by hCES1 
to meperidinic acid, an inactive metabolite. Heroin as well as its hydrolysis products possess agonist 
activity for opiate receptors. hCES1 catalyzed hydrolysis predominantly eliminates the amide 
rufinamide to its carboxylic acid. Then it is subject to either renal elimination or further 
glucuronidation previously to renal elimination (Perucca et al., 2008). 
The only clinical examples of CES substrates that are carbamates are the two oncology drugs, 
Capecitabine and irinotecan. hCES2 hydrolyzes the pro-drug capecitabine, but the product is a 
translational metabolite and it therefore has to be further metabolized by thymine phosphorylase 
and cytidine deaminase to form the active antitumor moiety, 5-fluorouracil. The formation of the 
active metabolite, 7-ethyl- 10-hydroxy camptothecin (SN-38), is the result of the hydrolysis of the 
pro-drug, irinotecan. It seems that both hCES1 and hCES2 are contributors to the hydrolysis of 
irinotecan to SN-38, but the hCES2 catalyzed hydrolysis is far more efficient. The administration of 
irinotecan is intravenously and entree to the utmost abundant expression of hCES2 located in the 
small intestine is thereby limited. However, hCES1 seems to play an imperative role in drug 
activation (Laizure et al., 2013).  
Mycophenolate is an immunosuppressant administered at the inactive ester mycophenolate mofetil. 
To form mycophenolic acid, an active drug, it therefore undergoes hydrolysis. Even though 
hydrolysis happens in the plasma, the liver and the intestine, in vitro studies have shown liver 
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hydrolysis by hCES1 to be the most effective pathway. This vulnerability to several esterases is not 
distinctive to mycophenolate mofetil. The majority of esters vulnerable to enzymatic hydrolysis are 
substrates of several esterases, which might be subject to spontaneous or non-enzymatic hydrolysis. 
In general, the efficiency of enzymatic hydrolysis is considerably superior for one specific esterase 
and the hydrolysis variability through this pathway controls the ester’s alteration rate to the 
analogous carboxylic acid and alcohol (Laizure et al., 2013). 
Role of CES’s in xenobiotic metabolism 
CESs are imperative contributors to xenobiotic metabolic pathways, counting drugs and pro-drugs. 
For some pro-drugs, such as irinotecan and prasugrel, the bio activation of the pro-drug is directly 
catalyzed by CESs. Still, CESs have the ability to facilitate the inactivation and clearance of both 
drugs and pro-drugs. The understanding of similarities as well as differences in CES activity 
between human beings and preclinical models of drug disposition is crucial, as evolving therapeutic 
agents using these hydrolytic pathways are being developed (Williams et al., 2011). Various illicit 
drugs, environmental pollutants and pharmaceutical agents contain ester bonds, which increase 
bioavailability and compound lipophilicity. Some examples are narcotics, plasticizers, pro-drugs, 
pesticides and anti-thrombotic drugs, such as aspirin. CES hydrolytic actions may inactivate or bio-
activate these compounds, depending on the compound. Various laboratories have focused on CES 
metabolism of pyrethroids due to their widespread use in public health and agriculture (Ross et al., 
2010). 
Human Carboxylesterase 1 
The hCES1 is a serine hydrolase responsible for metabolizing a broad variety of substrates, both 
endogenous and xenobiotic. Xenobiotic substrates of hCES1 include heroin, cocaine, lidocaine, and 
ACE inhibitors. Additionally hCES1 is thought to be part of the endogenous cholesterol 
metabolism, catalyzing hydrolysis of cholesterol and fatty acyl Coenzyme A (Bencharit et al., 
2006). The structure of the catalytic pocket recognizes widely diverse substrates, hCES1 mainly 
catalyzes the hydrolysis of compounds containing a larger acyl group or compounds containing a 
smaller alkyl group (Satoh and Hosokawa, 2006), as mentioned in; Metabolomics 
The flexible catalytic pocket recognizes a broad band of xenobiotics; see Table 5, but only a few 
endogenous substrates. See Table 6, which illustrates its enzymatic diversity and the broad 
selectivity (Thomsen et al., 2014).  
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Table 5: Xenobiotics that are broken down by hCES1, hydrolysis products and their therapeutic effect. Modified from 
(Laizure et al., 2013).  
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Table 6: Endogenous substrates for hCES1. 
Substrate Hydrolysis product Reference 
Cholesteryl ester (CEH) Chloresterol (Bencharit et al., 2006) 
Fatty Acyl CoA (FACoAH) Coenzyme A (Bencharit et al., 2006) 
Acyl-Coenzyme A  Cholesterol Acyltransfer (ACAT) Chloresteryl ester (Chloresteryl palmitate)
            
(Bencharit et al., 2006) 
hCES1 is expressed in several tissues in the human body such as the lungs, heart, adipose tissue, 
monocytes, macrophages and most abundantly in the liver. Expression of the CES1 gene in the 
human population seems to be remarkably constant between individuals. Contrarily, in the same 
individuals, enzymatic hCES1 activity differs considerably (Ross et al., 2010). Consequently, in the 
human population there is no simple correlation between hCES1 gene expression and hCES1 
enzymatic activity. Thus, a major factor accounting for the changing pharmacokinetic behavior of 
ester-containing xenobiotics in human populations might be post-translational hCES1 activity 
regulation. Alternatively, another variation contributor may be unidentified SNPs in the CES1 gene 
(Ross et al., 2010). A study performed by Friedrichsen et al investigating mRNA expression of 
hCES1 in adipose tissue has shown that there is no significant transcription increase in individuals 
with extra copies (three-four copies) of the hCES1 gene in relation to individuals with two copies  
(Friedrichsen et al., 2013). Sai et al showed that individuals with three or four copies of the gene (n 
= 35) had a 24 % increase in CES1 activity compared to people with two copies (n = 23), but the 
sample sizes were small (Sai et al., 2010). 
Genetic polymorphism of carboxylesterase 1 
The hCES1 gene is located on chromosome 16q13-q22.1, it comprises of 14 exons and spans about 
30kb. Gene variants have been investigated by several in order to explain differences in the 
metabolic activity of the hCES1 enzyme amongst individuals. Marsh et al conducted a study in 
2004 in which hCES1 was re-sequenced in populations of healthy African and European 
individuals. The study identified 16 hCES1 SNPs and none of the novel SNPs had any predictive 
value in relation to hCES1 activity and expression (Marsh et al., 2004). The allele frequencies are 
shown in Table 7. 
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Table 7: The structure and function of hCES1 haplotypes found in ≥5% in either the European or African population, or in 
both. Modified from (Marsh et al., 2004). 
 
Later in 2008, Yoshimura et al published a study in which hCES1 had been sequenced in a 
population of Japanese individuals. Polymorphisms where identified in the promoter region of 
CES1A2 affecting the promoter activity thus altering the efficiency of the ACE inhibitor drug 
imidapril by affecting the hCES1 mediated activation of the drug (Yoshimura et al., 2008). 
Additionally Zhu et al reported a study, using methylphenidate, which investigated individuals with 
an apparent malfunctioning breakdown of the drug. By sequencing hCES1 of the specific test 
subject, two mutations were found on the hCES1 gene resulting in a significantly lowered catalytic 
function of the hCES1 enzyme. One of the mutations showed a deletion leading to a premature stop 
codon resulting in a complete loss of catalytic activity. Subsequently DNA from 925 individuals 
was sequenced, none of which showed the same mutation as the individual of the previous study 
suggesting that the mutation is extremely rare (Zhu et al, 2008). The other mutation lead to a non-
conservative substitution. The 143GLU-variant and in vitro studies showed a 21% catalytic 
efficiency compared to the wild type. Respectively, the allele frequency of this mutation was 
determined to be 3.7% in Caucasians, 4.3 % in Black, 2% and 0% in Hispanic and Asians (Zhu et 
al., 2008).  
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A study by Nemoda et al further investigated this functional mutation (143Glu) and found that 
individuals diagnosed with Attention deficit hyperactive disorder (ADHD) that carried the relatively 
rare GLU allele of hCES1 required a lower dosage of methylphenidate when treated (Nemoda et al., 
2009). Furthermore, Johnson et al performed a study on 77 Japanese children diagnosed with 
ADHD and treated with methylphenidate. During the study they didn’t detect any relation between 
gene variants, dosage, and response. They did however find an association between two hCES1 
SNP and sadness as an adverse response (Johnson et al., 2013). 
A recent study performed by Yu-Jung Cha et al identified three novel hCES1 SNPs, which were 
classified as possibly damaging to protein function and structure. Two of the three SNPs have been 
investigated and have not shown to lower the hCES1 mediated metabolism of specific drug 
substrates. The SNP remaining has yet to be investigated (Cha et al., 2014). 
The present investigations of the effects of hCES1 genetic polymorphisms on hCES1 mediated 
metabolism has not resulted in a one-sided conclusion concerning the importance of genetics in 
relation to prediction of the hCES1 mediated metabolic activity. The 143Glu allele is the only 
determined SNP, which has proven to reduce the catalytic efficiency significantly. Additionally 
there is a great possibility that yet to be identified SNPs can be a determining factor for differences 
in hCES1 activity amongst populations. There may be many rare SNPs which will result in an 
impaired hCES1 mediated metabolism in an individual and together these will account for part of 
the variations observed amongst populations. Additionally there may be SNPs, both frequent and 
rare, that individually do not affect the activity of hCES1 but when several of them are present in 
one individual, it will result in a reduced hCES1 activity. Unidentified polymorphisms in regions 
outside the hCES1 gene and regulatory regions including unidentified inducers and inhibitors may 
as well be the cause of the individual variation in hCES1 activity.  
The structure of hCES1 
The hCES1 enzyme can be divided into three distinct functional domains. The catalytic site, the Z-
site and the alpha/beta domain. The catalytic site contains the active pocket, which harbors the 
catalytic triad. The Z-site is found in the regulatory domain and controls the trimer hexamer 
equilibrium of the enzyme. As the enzyme uses the surface of the Z-site to form the hexamer, the Z-
site is only able to bind ligands when the enzyme is in its trimeric state. Lastly, the alpha/beta 
domain is involved in stabilizing the trimeric structure of the enzyme and the release of product 
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molecules (Bencharit et al., 2006). The catalytic triad is located on the active site and is composed 
of SER221, GLU353 and HIS467, see Figure 7. 
 
Figure 7: Illustration of hCES1 as a monomer. The light red area is the N-terminal domain, the light blue area is the C-
terminal domain and the light yellow area is the αβ-domain. The Z-site is illustrated as an electron cloud around a 
taurocholate molecule. The active site, where many substrates reside under metabolism, is illustrated as a green colored 
electron cloud around another taurocholate molecule. The green side chains are the side chains which forms the catalytic 
triad (SER221, GLU354 and HIS468). The dark green areas are the catalytic pocket. The red and dark red areas are active 
sites, found by two docking analyses with nelfinavir and morphine, respectively. The area which is pointed out with a blue 
circle is the substrate binding gorge opening (Bencharit et al., 2006;Rhoades et al., 2012;Vistoli et al., 2010). The data for the 
illustration is the .pdb files 2DR0 (hCES1 taurocholate complex) and 4AB1 (hCES1 with no substrates) from RCSB.org. 
The catalytic triad of hCES1 is highly conserved amongst CES1 isozymes and the catalytic function 
may therefore be strikingly conserved amongst the isozymes too. The active site is comprised of a 
large ”flexible” pocket and a smaller ”rigid” pocket, see Figure 8A and B, providing a highly 
hydrophobic environment favorable for the hydrolysis of larger hydrophobic compounds. Part of 
the larger pocket is a small secondary pore referred to as the side door, shown in Figure 7.  This side 
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door allows smaller substrates and product molecules to enter and exit the active site to and from 
the surface of the enzyme.  The structure of the catalytic pocket recognizes widely diverse 
substrates (Satoh and Hosokawa, 2006). 
A study by Vistoli et al investigating the metabolism of hCES1 by docking analysis, showed the 
residues aligning the catalytic cavity of hCES1 to be mainly hydrophobic, see Figure 8A. The study 
additionally showed that the SER221 residue divided the catalytic pocket into two polar distinct 
cavities. Non-polar residues align the bigger more flexible pocket that accommodates the larger acyl 
groups and the smaller, more rigid pocket, is aligned by polar residues. These results by Vistoli et 
al, supports the theory that hCES1 mainly hydrolyses substrates with either a smaller alkyl group or 
a larger acyl group (Vistoli et al., 2010).   
 
Figure 8: Illustration of the catalytic pocket in hCES1. A) Simple illustration of the main residues in the catalytic pocket, the 
green residues are non-polar residues, H-bonding residues are blue, negatively charged residues are red and the catalytic 
triad residue SER is orange. Modified from (Vistoli et al., 2010). B) The main residues of the catalytic pocket, the C-terminal 
domain and Z-site. The same color scheme, as for picture A is used. C) hCES1 with the main residues in the catalytic pocket 
colored in the same colors as in picture A and B. The light red area is the N-terminal domain, the light blue is the C-terminal 
domain and the light yellow is the αβ-domain. The data for illustration A and B is the .pdb files 2DR0 (hCES1 taurocholate 
complex) and 4AB1 (hCES1 with no substrates) from RCSB.org. 
The role of CES1 in metabolism of endogenous compounds  
Lipid metabolism 
Ko et al found that CES1 limits hepatic accumulation of triglycerides by promoting beta-oxidation 
of fatty acids (a multi-step process in which fatty acids are broken down by various tissues to 
produce energy) (Ko et al., 2009). Furthermore, Freidrichsen et al suggested that CES1 in adipose 
tissue is involved in both the trans-esterification and de-esterification of lipids (Friedrichsen et al., 
2013). 
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Xu et al investigated the role of hepatic Ces1 in lipid metabolism in mice, which showed that an 
overexpression of hepatic Ces1 resulted in a lowered hepatic triglyceride level and plasma glucose 
level in both diabetic and non-diabetic mice. Furthermore a knock down of Ces1 showed an 
increase in hepatic triglyceride and an increase in plasma cholesterol levels. It is suggested that 
Ces1 performs triglyceride hydrolysis which in turn is followed by changes in the oxidation of fatty 
acids. Interestingly, they did not find lowered plasma cholesterol by overexpression (Xu et al., 
2014).  
Cholesterol 
hCES1 performs hydrolysis of cholesteryl ester. Releasing an alcohol substituent from the substrate 
results in a fatty acyl enzyme complex intermediate. This intermediate then reacts with water 
resulting in a release of the molecule containing the acyl group. Additionally hCES1 acts as a 
transferase, catalyzing the formation of cholesteryl esters in case of abundance of free cholesterol 
(Friedrichsen et al., 2013). 
Inhibition of hCES1 results in an inhibition of cholesteryl ester hydrolysis in human macrophage 
cells and thereby decreases cholesterol efflux from human macrophage foam cells (Crow et al., 
2008;Igarashi et al., 2010).  
Zhao et al showed that hCES1 depletion reduced CES hydrolytic activity with more than 70%, 
indicating that hCES1 proteins account for about 70% of intracellular CES hydrolysis. However, 
Ces1 knock down (KD) did not decrease intracellular cholesteryl ester (CE) hydrolysis or free 
cholesterol efflux, in human THP-1 monocytes. The CES1KD macrophages showed about a 30% 
increase in human carboxylesterase 3 (hCES3) expression, which led to an increase in the CE 
hydrolytic activity. They concluded that hCES3 could be a carboxylesterase which was up regulated 
when hCES1 was KD (Zhao et al., 2012). Ross et al showed that despite efficient KD of hCES1 
protein expression there was no significant difference in the percentage of cholesterol efflux to 
ApoA1 when hCES1KD macrophages was compared to control macrophages in human THP-1 
monocytes, and free cholesterol levels were unchanged. They also found that the hCES1KD THP-1 
macrophages’ CE level was significantly lower than that in control THP-1 macrophages both before 
and after efflux. hCES3 mRNA was up regulated but hCES3 activity was not increased. This led 
them to believe that hCES3 does not compensate for hCES1 loss of function (Ross et al., 2014).  If 
this is the case, it is likely that cholesteryl ester could be a likely biomarker for hCES1 activity. 
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Glucose 
Xu et al proposed that CES1 expression is directly regulated by glucose due to the fact that a high 
glucose level in mouse primary hepatocytes induced hepatic Ces1 mRNA expression. Their data 
showed that glucose stimulates Ces1 activity through a region between 75bp and 150 bp upstream 
of the transcription site (Xu et al., 2014). Furthermore, Xu et al showed that ATP-citrate lyase, 
which converts glucose-derived citrate to acetyl-CoA used in glucose-mediated histone acetylation 
(Wellen et al., 2009) is required for the glucose-mediated acetylation of H3 and H4 in the Ces1 
chromatin (Xu et al., 2014). Xu et al suggested that due to this, glucose induces Ces1 expression, 
Ces1 regulates glucose metabolism, and hepatic Ces1 may regulate blood glucose levels after a 
meal (Xu et al., 2014). This makes glucose an interesting factor in future research of biomarkers for 
hCES1 metabolism. 
In all of the above mentioned studies of CES1 metabolism, a common hindrance is that endogenous 
compounds metabolized by CES1 in most cases are metabolized by other enzymes too. This makes 
it more difficult to study the pathway and outcome of the CES1 metabolism and applying this to 
hCES1 metabolism.  
Allosteric functions of hCES1 
hCES1 is known to be promiscuous regarding substrate specificity (Bencharit et al., 2003;Bencharit 
et al., 2006;Fleming et al., 2005;Williams, 1985). This has led to the theory that hCES1 or some of 
its sites have allosteric functions. In 2005 Fleming et al proposed, that the flexibility of hCES1 was 
not due to the large pocket but due to the Z-site, which lies above the large pocket (Fleming et al., 
2005). By combining the Bencharit et al study, from 2003, with their own data, Fleming et al 
suggested that ligand binding to the hCES1 Z-site shifts the enzyme’s trimer-hexamer equilibrium 
toward the trimer, thus facilitating the binding of substrates within the active site (Bencharit et al., 
2003;Fleming et al., 2005). This suggests that the flexibility and movement of the large pocket 
makes the movement and allosteric functions of the Z-site possible though the pocket does not have 
an allosteric function itself.  
In 2006, Bencharit et al investigated hCES1’s lack of substrate specificity and found data that 
supported the hypothesis suggested by Fleming et al in 2005. Furthermore the data suggested that 
the Z-site is capable of binding to cholesterol-like molecules, which might play a role in the 
biological activity of the enzyme when processing cholesteryl esters and other endogenous 
substrates.  
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Additionally Bencharit et al suggested that the Z-site may facilitate the proper positioning of the 
catalytic triad residue Glu354 for catalysis. This was based on structural insights in the function of 
the rabbit liver CE Z-site and kinetic data from previous experiments (Bencharit et al., 
2002;Bencharit et al., 2006;Fleming et al., 2005). These suggestions presented are coherent with the 
known promiscuity of hCES1, and the fact that 3A4 has been shown to have a similar ligand 
binding site on its surface, adjacent to its active site (Bencharit et al., 2006;Williams et al., 2004), it 
is possible that hCES1 has a similar site. As both 3A4 and hCES1 are important drug metabolizing 
liver enzymes, in the specific enzyme families they belong to, the allosteric sites in 3A4 and hCES1 
suggest that conformational change is imperative in drug metabolizing enzymes (Imai et al., 
2006;Williams et al., 2004). It is proposed that the peripheral binding site on 3A4 functions in 
substrate screening and allosteric regulation. Therefore Bencharit et al suggests that hCES1’s Z-site 
has the same function. This is supported by previous data (Bencharit et al., 2003;Bencharit et al., 
2006;Fleming et al., 2005;Williams et al., 2004).  
The flexibility of hCES1 is creating a diverse enzyme that can add to the recognition of xenobiotics, 
and thereby dealing with substrates that the other enzymes cannot (Thomsen et al., 2014) 
Discussion 
Adverse effects 
When considering the extensive research needed to find and implement a possible biomarker or 
probe for hCES1, it is necessary to analyze whether the possible benefits, the effort and financial 
costs are worth it.  
If the minority of patients treated experience adverse effects or if the adverse effects are 
insignificant, is finding a biomarker or probe then beneficial? If only a minor quantity of drugs 
commonly used are metabolized by hCES1, is hCES1 then significant to research? hCES1 
metabolizes several xenobiotic compounds and about half of these, are pro-drugs. Hence, no hCES1 
activity results in no therapeutic effect, as the compound is not efficiently metabolized. This is the 
case for many ACE-inhibitors, antihyperlipidemic agents, immunosuppressive agents and antiviral 
agents, hCES1 metabolizes. Additionally, a prolonged drug exposure and high amounts of active 
compounds present in the body is associated with adverse effects.  
 
 Page 37 of  75 
 
Severe or fatal adverse effects are not common amongst xenobiotics metabolized by hCES1 so 
when looking into hCES1 mediated drug metabolism and finding biomarkers or probes, the aim is 
not just to save lives but to improve the life quality of patients who experience less severe, but long-
term adverse effects.  
An example of a common adverse effect in ADHD patients treated with methylphenidate is 
insomnia. Many patients diagnosed with ADHD are subject to prolonged treatment using this drug. 
Even though this adverse effect in some perspectives could be considered relatively mild, in a long-
term perspective it can result in a significantly lowered quality of life as it damages the patient’s 
daily life. Another aspect that has to be considered is the size of the therapeutic window of the drug. 
Research in pharmacokinetic profiling is relevant when treating with a drug that has a very narrow 
therapeutic window. 
 
Pharmacokinetics play a crucial role in controlling drug exposure. The longer drugs are active and 
in high concentrations, the greater the probability of ADR. Thus, an ultra-rapid metabolizer will 
experience a quick increase in the plasma concentration of the active compound of a pro-drug and a 
rapid decrease in the plasma concentration of a non-pro-drug. The accumulation of drugs is thereby 
mainly controlled by pharmacokinetics, which also affects efficacy and ADR. The increased or 
decreased exposure may result in a plasma concentration below or above the therapeutic window 
and can additionally cause ADR or result in no beneficial effect of the drug. In contrast to CYP2D6 
in which SNPs determine the function or non-function of the enzymes and to pharmacodynamics 
that is regulated by gene variants, hCES1 is not known to be highly regulated by gene variants and 
is likely regulated by induction and inhibition of the enzyme.  
Research showed that CYP3A4 is an excellent model in this type of regulation. When the drug 
lurasidone is administered with an inhibitor or an inducer, Cmax and AUC changes. The same 
change was observed in the lurasidone plasma concentration in which a higher plasma 
concentration increases the likelihood of ADR.  As hCES1 might be altered by both inducers and 
inhibitors, this alteration have an important influence on drug metabolizing enzymes and the plasma 
concentration (Caccia et al., 2012).  
Alleles’ and SNPs’ influence on enzyme activity 
As earlier mentioned, CYP2D6 is highly regulated by allele variants. The alleles have a significant 
impact on the regulation of the enzyme activity. Variant 2D6: *3,*4,*5 and *6 show a total loss of 
allele function and the frequencies of these alleles are significant, up to 25% in some ethnic groups. 
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Variant 2D6: *10, *17, *41, are all SNP’s which causes a decrease in enzyme activity and 
expression. These variants are also seen at high frequencies, especially *10 is seen in up to 70% of 
Asians. For hCES1 one functional SNP is determined that result in 21% of catalytic efficiency in 
relation to that of a wild type. This allele is as well relatively rare and is most frequent in Caucasian 
and African populations where it shows an allele frequency of 3.7% and 4.3% respectively (Zhu et 
al., 2008). 
 
For the two enzymes 2D6 and hCES1, no clear resemblance appears amongst the significance of 
polymorphisms. However, it is proven that hCES1 activity is subject to genetically determined 
decreases in catalytic function due to SNPs. One SNP decreases the catalytic efficiency to 21% with 
an allele frequency at a maximum of 4.3%. This is not sufficient to explain the apparent variation in 
the hCES1 enzyme activity among individuals in populations. Contrarily individual variation in 
CYP2D6 activity and expression is clearly regulated by SNPs in the genome and can be explained 
by the genotype of a patient.  
 
Studies show that 2D6 expression increases when the copy number of the 2D6 gene increases. In 
contrast, studies have shown that an increase in CNV in hCES1 does not result in a significant 
increase in hCES1 expression and activity (Friedrichsen et al., 2013;Zhu and Markowitz, 2013). 
Additionally studies have identified novel SNPs yet to be investigated in relation to the impact on 
enzyme activity.  
Newer research are making it clearer that the activity cannot only be explained by the gene and the 
variants that may show up, there is properly another regulatory mechanism which explains the 
regulation at substrate level. 
Conformational changes affecting function and activity 
As previously mentioned, hCES1's substrate promiscuity can be explained by allosteric functions 
mainly at the Z-site. When the Z-site interacts with a substrate it promotes conformational changes 
and thereby allows larger or smaller molecules to protrude and fit in the catalytic site. Furthermore, 
the side door permits part of the molecules to protrude the side door, which facilitates the 
promiscuity. The same allosteric functions are the main explanation for 3A4's substrate promiscuity 
and is why it is used as a model for hCES1. The substrate promiscuity in both enzymes makes it 
difficult to determine a substrate to use as a possible biomarker. The allosteric regulation of these 
enzymes changes the affinity for the substrates and finding only one biomarker is therefore 
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complicated. For 3A4, three biomarkers have been suggested and are to some extent used, but 
similar discoveries has yet to be done for hCES1. Even though 3A4 has a high substrate 
promiscuity, it has peripheral binding sites capable of substrate screening too. While there are no 
correlations between the substrate screening and exclusion of specific substrates, data proposes that 
hCES1's Z-site has the same substrate screening capabilities. It is known that hCES1 prefers 
molecules with a high acyl moiety, which could be due to a positive substrate screening quality at 
the Z-site. If the Z-site has no positive substrate screening quality it may just promote binding 
affinity to substrates. The substrate screening quality of the Z-site can be investigated using a 
simple molecule with an acyl group in one end and a non-polar group at the other end. If this fits 
and in some way interacts with the Z-site, the positive substrate screening is possible. If not, the 
high acyl moiety preference of hCES1 could be due to the amino acids lining the large catalytic 
pocket. If the Z-site has a negative substrate screening quality it will be able to exclude compounds 
and by identifying which substrates it can exclude it could narrow down the possible biomarkers for 
hCES1. Furthermore, the acyl moiety preference could be utilized further by adding acyl 
compounds to the possible biomarkers. The modified substrate might lose the affinity for other 
enzyme pathways and thereby only has hCES1 as its catalyzer. 
Inhibitors and inducers 
Similarities are found when comparing hCES1 with CYP2D6 and CYP3A4. These similarities 
suggest that the enzyme function is a combination of the two CYP's main abilities. As 2D6 and 
3A4, hCES1 metabolizes a large portion of different xenobiotics, however 3A4 metabolize a 
broader spectrum of xenobiotics than 2D6, indicating that 3A4 has the widest metabolizing ability. 
hCES1 is known to be a predominant drug metabolizer in the liver suggesting that it has similar 
qualities as 3A4. Nevertheless, as 2D6, hCES1 has no known inducers implying that these two are 
more comparable. Can it be determined which of the CYP's that is equivalent to hCES1 based on 
the ability to be induced by endogenous or xenobiotic compounds, it should be possible to base the 
same equivalency on the inhibitors known for each of the enzymes. Although different compounds 
inhibit the enzymes, some inhibit the same enzymes. 
 
To find the most convenient model for hCES1, other similarities are considered; though it is rare, 
hCES1 as 2D6 shows some genotypic decreases in activity. Contrary to 3A4, no inducers for 2D6 
are found, and only very few for hCES1. The above mentioned combined with the allosteric 
functions of hCES1 that shows similarities to 3A4, the most useful CYP model for hCES1 might 
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not be one of the CYP's, but a combination of both. Therefore, the most efficient method in 
determining the hCES1 phenotype is to measure the actual enzyme activity through biomarkers or 
probes. The model of genotyping from 2D6 can be used to explain some of the activity, while 3A4 
explains the flexibility of the structure and why the actual metabolism must be measured throughout 
phenotyping. 
The complexity of finding probes and biomarkers for the activity of hCES1 
A way to further personalize medical treatment with the aim to diminish symptoms more efficiently 
and minimize adverse responses, is to determine the activity of hCES1 by identifying a probe or 
biomarker that can be used as a proxy for the hCES1 activity as it has been done with testosterone 
and cortisol as biomarkers for CYP3A4 activity. Finding a biomarker for hCES1 is difficult due to 
the few identified endogenous substrates. Contrarily there are plenty of xenobiotics, which may be 
possible probes in determining the phenotype.  
 
All the identified endogenous substrates for hCES1 are part of several pathways metabolized by 
other enzymes as well as by hCES1. Thus, it is complex to determine one specific substrate and 
product as an eligible suggestion for a hCES1 activity biomarker. If the amount of metabolizing 
effect hCES1 contributes with to the cholesteryl ester metabolism, or the metabolism of other 
endogenous substrates can be determined, these could be suggested as possible biomarkers. These 
biomarkers can be used to determine different profiles. If the metabolizing effects of other enzymes 
to the pathway is known, it can help estimating the hCES1 activity. Nevertheless, this requires an 
extensive metabolomic investigation into the cholesteryl ester metabolism pathways in the body. 
Therefore, a xenobiotic compound used as a probe would possibly be a more qualified way to go, 
excluding endogenous substrates as useful biomarkers. Currently, using known probes to determine 
phenotypes of patients is too complicated for clinical practices.  
 
As mentioned before, two endogenous substrates is identified and are clinically applied biomarkers 
for 3A4. In contrast to the endogenous hCES1 substrates, other enzymes do not metabolize the 
endogenous substrates, metabolized by 3A4. If a xenobiotic compound is used as a probe for 
hCES1, it has to be non-toxic both as a substrate and as a hydrolytic product. In addition, in order to 
be considered a probe, it has to be effectively metabolized to prevent accumulation of metabolites. 
Furthermore, the risk of adverse effects in xenobiotic probes has to be considered. The process of 
identifying substrates by hCES1’s substrate promiscuity is complicated. If the Z-site substrate 
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screening process and the elimination of compounds is investigated further, it might be possible to 
invent a qualification method excluding possible substrates in the search for a probe detecting 
hCES1 activity. Finding a useful xenobiotic substrate for hCES1 may be possible as this method of 
using xenobiotic probes or biomarkers already are established for 3A4 and are, like hCES1, 
characterized by broad substrate specificity.  
Probes for hCES1 
The only known probe for hCES1 that shows a significant specificity is derived from 2-(2-hydroxy-
3-methoxyphenyl) benzothiazole (HMBT). The probe (probe 1) is fluorescent and developed to 
monitor the hCES1 activity by introducing benzoyl moiety to HMBT giving it a high hCES1 
affinity. Probe 1 can be used to perform a qualitative analysis of the enzyme activity in vitro. The 
probe shows a low toxicity for living cells and can therefore be used on living hepatocytes. In Liu et 
al, the team using this probe, succeeded performing this method on living hepatocytes. This study is 
the first to determine an applicable probe for hCES1 activity and though there is a background 
signal from hCES2 activity, it is statistically insignificant. 
 
The discovery of probe 1 opens up new possibilities for hCES1 phenotyping and use in vivo. As 
hCES1 primarily is expressed in the liver and the small intestine, these are the optimal test tissue. 
The hepatocytes and epithelia of the small intestine is nearly impossible to achieve and the 
procedure of diagnosing a patient may not be beneficial when a cost-benefit perspective is 
considered. Although, to achieve a more precise measurement of hCES1 activity, testing on the 
liver or the small intestine is preferred as the allosteric regulation may be different compared to 
tissue with a lower expression level. The advantage of using tissues in which regulation may be 
different, such as monocytes and macrophages, is the accessibility (Sanghani et al., 2009;Satoh et 
al., 2002). Monocytes and macrophages are easily extracted as well as tested in blood. Probe 1 
makes it possible to use blood samples to detect the hCES1 phenotype, which also has been 
suggested by Liu et al. 
Metabolomics 
Probe 1 is, as previously mentioned, the only probe identified for hCES1. Since the probe is only 
used on living hepatic cells, it is not yet certain whether the method is clinically applicable but 
monocytes may be a new opportunity. If the method does not show valid results when used on 
easily accessible cells such as macrophages and monocytes, the procedure may be too invasive for 
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regular clinical use. Metabolomics would therefore be an obvious and possibly more suitable 
approach to test the endogenous substrates, as they are easily accessible through blood samples. 
Cholesteryl ester (CEH), Fatty Acyl CoA (FACoAH) and Acyl-Coenzyme A Cholesterol 
Acyltransfer (ACAT) are three endogenous substrates which hCES1 metabolizes. Since these 
substrates act as intermediates in many pathways to become their representative product they cannot 
be used solely for a qualitative measurement to predict hCES1 activity. By using metabolomics, all 
of these substrates can be measured at once.  
 
As the hCES1 activity cannot be detected by measuring a single substrate, the other pathways may 
be the answer to solve the equation. The other pathways that metabolize the endogenous substrates 
can be measured by other substrates and their activity can be determined too. If the enzyme activity 
of the other pathway are normal, the lowered endogenous concentration of CEH, FACoAH and/or 
ACAT would be due to hCES1. Therefore, the three metabolite-markers CEH, FACoAH and 
ACAT, can be used to detect whether the activity of hCES1 is normal, increased or decreased in an 
indirect way. As this method requires a more extensive research into which pathways contribute to 
the endogenous concentration of CEH, FACoAH and ACAT and their products, it might not be 
optimal for measuring hCES1 activity though it might be the only possible approach. Since 
metabolomics measure all metabolites and not only a single pathway, other pathways may 
synthesize metabolites. When metabolites are developed through multiple pathways, a single result 
may not be sufficient. When other pathways are used as an indicator, complications might occur if 
the pathway is either induced or inhibited. This will change the ratio of all the pathways and can be 
used as a proxy for hCES1 activity. If focusing on one pathway in order to see whether the 
substrate/product ratio changes, these values can be determined as a standard and used to determine 
different turnover-profiles. Nevertheless, an unknown disturbance may too result in a biased 
diagnosis of the hCES1 phenotype. Background noise may decrease as metabolomics can be used 
on great amounts of metabolites. 
 
The above mentioned procedure can be applied on xenobiotics metabolized by hCES1. These can 
be used as metabolite-markers in metabolomics as a quantitative analysis. The obstacle when using 
xenobiotics is the high risk of toxicity. To use these xenobiotic metabolite-markers they must run 
down the same pathway as the intermediates and must have an insignificant toxicity. The possibility 
of ADR is probably the limiting step when using xenobiotics as metabolite markers. If these 
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requirements are not met, the above-mentioned method will not be applicable when conducting a 
cost benefit analysis. 
Conclusion 
Pharmacokinetics, more specifically the metabolism of drugs, is a major determinant for drug 
response. The activity of drug metabolizing enzymes does not only determine the therapeutic effect 
of the treatment but also the likelihood for adverse effects. The dose-dependent response, including 
both the therapeutic response and ADR are highly related to the rate of drug metabolism, meaning 
the activity of drug-metabolizing enzymes, such as hCES1, is of great importance to the drug 
response. When a drug has a narrow therapeutic window, it is increasingly important to estimate the 
hCES1 activity and target the plasma concentration of the drug within the therapeutic window.  
 
 
When predicting the metabolic activity of hCES1, CYP2D6 and CYP3A4 can be used as models. 
However, as the previous discussion suggests it is not sufficient to use only one CYP as a model, as 
hCES1 activity cannot be fully explained by neither the 2D6 model nor the 3A4. hCES1 exhibits 
genetic variation and enzyme alteration, which makes it is necessary to consider both models. 
Likewise it is not possible to find a direct correlation between enzyme activity modulation and 
substrates, inhibitors and inducers, and thus not possible to determine one single CYP model to 
predict hCES1 activity modulation.  
 
Studies of Probe 1 shows low toxicity and a significant specificity for hCES1 in hepatic cells. These 
results indicate that this probe is a promising candidate for clinical trials in cells expressing hCES1.  
Further tests in biological samples are needed to determine the efficiency in distinct cell types. 
Currently, studies have solely been performed in vitro on hepatic cells and it is still uncertain if this 
method can be applied in a clinical perspective.  
 
Since genotyping does not provide a complete picture of the activity, another approach could be to 
apply metabolomics in which many endogenous substrates are taken into consideration. In 
metabolomics, many metabolites are contemplated to determine enzyme activity, which makes this 
method applicable regardless of whether the enzyme activity is under genetic control or if it is 
influenced by other parameters. 
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The only useful probe, probe 1, is tested on poorly accessible tissue samples hence the use of 
biomarkers or probes for hCES1 in clinical treatment is not possible. Gene markers were used but 
did not explain the enzyme activity. In the future, with extensive research on mechanisms 
highlighted in this project, finding a biomarker for hCES1 activity that is easily accessible which 
eventually can be clinically applied is possible.  
 
Considering that no useable biomarkers or probes for determining hCES1 activity are found, 
looking into other methods such as metabolomics may be useful. Numerous enzymes that are part 
of other pathways metabolize various endogenous substrates also metabolized by hCES1. This 
makes metabolomics an evident method to apply to the hCES1 activity determination predicament.  
 
In order to apply metabolomics to the determination of enzyme activity, extensive research is a 
necessity, as several different parameters and metabolites have to be investigated. Still, it may 
ultimately lead to a better estimation of the actual enzymatic activity. 
Perspective  
This study shows that determining the pharmacokinetic profile of a patient can be complex.  It is 
necessary to consider the time and resources required for profiling a patient in relation to the 
possible beneficial outcome. Furthermore, some medical conditions are acute which makes 
profiling before giving the necessary treatment impossible due to the lack of time.  
Extensive research into metabolomic pharmacokinetic profiling may make it possible to profile a 
patient by analyzing blood samples resulting in a spectrum and a metabolite substrate ratio. The 
spectrum is then compared to a known pharmacological profile providing an inexpensive method 
with an immediate answer. This saves resources by reducing the amount of patients revisiting 
medical professionals due to experienced adverse effects or due to the lack of therapeutic effect. 
For example, a normal metabolite/substrate ratio is investigated to determine a normal pharmaco-
kinetic profile and additionally determine the profile of a poor –or an ultra rapid metabolizer. These 
profiles can be used in comparison when estimating the pharmacokinetic profile of a patient. 
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Supplements 
Docking experiment 
Introduction 
Docking is an in silico method for determining the affinity between a compound and a receptor or 
an enzyme. In this docking experiment, the compounds are tested on the enzyme hCES1. Docking 
is among others used to assess whether a specific compound will bind to an enzyme and based on 
the affinity where within the enzyme or at which sites it binds. Solely based on a docking 
experiment, where the compound will bind in vivo or in vitro cannot be concluded but the docking 
can tell if a compound will bind and where the affinity is highest (Grosdidier et al., 2011). 
Methods 
SwissDock was used for several docking analyses of the interactions of different compounds with 
hCES1. The output from SwissDock was used to compare the affinity of the selected compounds 
for hCES1 and cannot be used to determine any kind of interaction between hCES1 and the 
compound. The three compounds selected have known in vitro properties when interacting with 
hCES1. These data show which affinity profiles a substrate, an inhibitor and a negative reference 
compound have when interacting with hCES1. To simplify the in silico experiment, only the ΔG, 
the FullFitness and the location of a ligand within the enzyme are included. The docking experiment 
is conducted from three test subjects: 27-hydroxycholesterol, used as a strong inhibitor, cholesterol, 
used as a negative reference (Crow et al., 2010) and methylphenidate as substrate and a positive 
control (Yang et al., 2014). The objective with these three substances is to determine how the 
FullFitness and ΔG change compared to the expectations. As hCES1 undergoes conformational 
changes when interacting with a compound the enzyme was allowed 5Å flexibility in the docking 
analyses. 
 
Docking shows, the possible and viable interactions a compound can undergo within an enzyme. 
The possible interaction sites depicted which leads to a modulated activity and the role of the 
compounds used, are based on our knowledge from the previous theory section giving us the 
possibility to determine where the site of action should be and the possible correct interaction. 
Nevertheless, as docking is an in silico experiment and is dependent on the users’ knowledge of 
different interactions within an enzyme, the results are not conclusive. The results are preferentially 
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verified using a 3D crystallography and if confirmed, further verification using an in vitro model 
can be a possibility. 
 
The docking of the three compounds cholesterol, 27-hydroxycholesterol and methylphenidate 
resulted in about 240 viable docking models. To reduce this number, ΔG for the viable model of 
methylphenidate within the catalytic pocket was used as a limit for the viable model of the negative 
reference, cholesterol, and the strong inhibitor, 27-hydroxycholesterol. Based on the docking of 
methylphenidate, two models are possible. These are the only two models in which 
methylphenidate is close to the catalytic pocket. These two models respectively have a ΔG of -6.6 
and -6.8. Based on this, the negative reference cholesterol, which does not act as a substrate or 
inhibitor will have a ΔG above -6.6 because the binding and therefore the energy of the reaction, 
will not be favorable. The strong inhibitor, 27-hydroxycholesterol, will have a ΔG of -6.6 or below 
as it is a favorable reaction, and has a high affinity. 
  
Results 
When limiting the amount of possible models for the negative reference, cholesterol, it resulted in 
19 different cluster groups, see Appendix #1 for a cluster comparison. For the inhibitor, 27-
hydroxycholesterol, the limitation resulted in 23 clusters, see Appendix #2 for a cluster comparison.  
The models with the highest and lowest ΔG and FullFitness values from the selected clusters were 
found and the average was calculated for each of the compounds, see Appendix #3. These were 
used for further analysis, see Table 8. 
Table 8: Data from docking with 5Å flexibility. It is apparent that there is some sort of correlation between ΔG and the 
FullFitness, although this correlation is much more obvious when looking at methylphenidate.   
 ΔG (Kcal/mol) FullFitness 
27-hydroxy average -7.04222 -2412.33 
Cholesterol average -6.317 -2400.72 
Methylphenidate #1.241 and #1.244 -6.79 and -6.607 -2473.488 and -2472.282 
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As the data are sorted, based on ΔG of methylphenidate, the result is not surprising. Nevertheless, 
only a few models did not fit the expected and were excluded from the 27-hydroxycholesterol and 
cholesterol docking data.  
 
The results indicate the affinity is highest for the inhibitor, then the substrate, and last cholesterol, 
which makes sense. When comparing the binding of substrates to other biological systems, the 
outcome is as expected, except for cholesterol as it does not have any influence on hCES1 activity 
and probably does not have a high affinity for the hCES1 complex at all. When comparing ΔG with 
the FullFitness result for each compound, it is apparent that FullFitness is lowest for the substrate 
and that no direct correlation between FullFitness and ΔG for the inhibitor nor for the negative 
reference is found. When comparing ΔG and FullFitness for the individual clusters there is to some 
extent a correlation for the inhibitor and the negative reference. This could be due to the inhibitor 
and negative reference not having to fit within the enzyme as they are not metabolized by the 
enzyme.  
 
Binding sites 
The binding site for the substrate methylphenidate is limited to the catalytic site, shown in Figure 9, 
and two docking models with the ability to bind within the catalytic site were found.
 
Figure 9: Illustration of the methylphenidate docking outcome when the two models in which methylphenidate resides within 
the catalytic pocket are selected. 
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Based on the docking analysis there are multiple possible binding sites for the inhibitor 27-
hydroxycholesterol. The binding site with the highest affinity is shown in Figure 10. The binding 
site with the highest affinity was expected to be near the Z-site, the side door or in one of the 
catalytic pockets as these sites are imperative for the binding of a substrate.  
 
 
Figure 10: Illustration of the 27-hydroxycholesterol hCES1 binding model with the highest affinity. This does not necessarily 
indicate that 27-hydrocycholesterol will bind at this site in vitro or in vivo. Additionally it was not expected that it would bind 
as illustrated or inhibit hCES1 as it is distanced from any known crucial hCES1 activity sites. 
Nevertheless, the high affinity of the above shown cluster, does not necessarily mean that this is the 
actual binding site of the inhibitor 27-hydroxycholesterol. Additionally, as shown in Figure 11, 
there are possible binding sites that match the expected ΔG for the inhibitor. 
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Figure 11: Illustration of the possible binding sites for 27-hydroxycholesterol when interacting with hCES1. The right hand 
clusters or the clusters in the N-terminal region (upper left clusters) were expected as these are regions of interest when 
looking at hCES1 activity regulation. The sites are near known structures that are crucial in the allosteric modulation, the 
side door (upper left) and the catalytic pocket (right hand side). 
Discussion 
The results from the three docking experiments show that ΔG and FullFitness do not necessarily 
correlate and do not show enough proportional behavior to be used as a limiting factor when 
considering the binding site of an inhibitor. However, these values do not need to follow the same 
pattern as they describe two different parameters: the affinity (ΔG) and the “hand in glove” situation 
(FullFitness). Furthermore, ΔG is not applicable as a deciding factor when considering the exact site 
an inhibitor will bind to but can be used as a limiting factor when defining the parameters in which 
an inhibitor should fit as the affinity is significantly higher for the inhibitor and the substrate than 
for the cholesterol. With a limited knowledge of hCES1 function, the use of positive and negative 
test subjects is necessary to elect substances before biological trial, and docking is reliable when 
singling out substances.   
The structure of the compounds used in the docking can be seen in Appendix #4 and the results and 
calculations for 27-hydroxycholesterol and cholesterol can be seen in Appendix #3. If we had time 
it could have been interesting to do the same experiment with the other known inhibitors of hCES1, 
seen in Appendix #5. 
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Appendices 
Appendix #1 
A comparison of the clusters in the cholesterol hCES1 docking analysis, before and after the 
removal of cluster which did not meet the ΔG criteria. 
 
Appendix #2 
A comparison of the clusters in the 27-hydroxycholesterol hCES1 docking analysis, before and after 
the removal of cluster which did not meet the ΔG criteria. 
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Appendix #3 
Tables showing the calculations and results used in the docking experiment for 27-
hydroxycholesterol and cholesterol. 
 27-
hydroxycholesterol 
     
Cluster Model Total 
number 
of 
models 
ΔG Average of 
the cluster 
FullFitness Average for 
the cluster 
0 #1.7 (8) 2 -7,511 -7,883 -2416,674 -2420,461 
0 #1.1 (2, 3, 4) 4 -8,069 
 
-2422,355 
 1 #1.13 (14, 15, 16) 4 -7,056 -7,117 -2417,496 -2418,225 
1 #1.9 (10) 2 -7,239 
 
-2419,681 
 2 #1.17  1 -7,440 -7,486 -2417,686 -2417,054 
2 #1.20 (21, 22, 23, 24) 5 -7,495 
 
-2416,927 
 3 #1.31 (32) 2 -7,263 -7,288 -2417,513 -2417,601 
3 #1.25 (26, 27, 28) 4 -7,301 
 
-2417,646 
 4 #1.38 (39, 40) 3 -7,186 -7,299 -2415,501 -2416,321 
4 #1.33 (34) 2 -7,468 
 
-2417,551 
 5 #1.46 (47, 48) 3 -6,951 -7,045 -2413,739 -2415,216 
5 #1.42 (43, 44, 45, 46) 5 -7,102 
 
-2416,102 
 6 #1.52 1 -7,104 -7,181 -2413,982 -2413,267 
6 #1.53 (54, 55, 56, 57) 5 -7,196 
 
-2413,125 
 7 #1.57 (58) 2 -6,718 -6,738 -2414,370 -2414,351 
7 #1.59 1 -6,779 
 
-2414,312 
 8 #1.69 1 -6,625 -7,005 -2413,243 -2413,483 
8 #1.67 (68) 2 -7,195 
 
-2413,603 
 9 #1.78 (79, 80) 3 -6,696 -6,767 -2413,107 -2413,471 
9 #1.73 (74) 2 -6,874 
 
-2414,017 
 11 #1.95 (96) 2 -6,798 -6,826 -2412,538 -2412,998 
11 #1.89 (90, 91) 3 -6,844 
 
-2413,304 
 12 #1.97 (98, 99) 3 -6,858 -6,881 -2411,977 -2411,854 
12 #1.102 (03, 04) 3 -6,905 
 
-2411,731 
 
13 
#1.107 (08, 09, 10, 
11) 5 -6,609 -6,665 -2411,191 -2411,251 
13 #1.105 (06) 2 -6,803 
 
-2411,400 
 14 #1.120  1 -6,651 -6,902 -2402,603 -2405,855 
14 #1.117 1 -7,154 
 
-2409,107 
 16 #1.133 (34, 35, 36) 4 -6,891 -6,981 -2409,602 -2410,057 
16 #1.129 (30) 2 -7,160 
 
-2410,969 
 17 #1.143 (44) 2 -6,775 -7,493 -2408,441 -2409,516 
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17 #1.137 (38, 39) 3 -7,971 
 
-2410,232 
 19 #1.156 1 -7,278 -7,334 -2407,384 -2408,252 
19 #1.153 1 -7,389 
 
-2409,120 
 
20 
#1.157 (58, 59, 60, 
61) 5 -6,924 -7,012 -2408,912 -2408,170 
20 #1.170 (71, 72) 3 -7,159 
 
-2406,932 
 21 #1.183 1 -6,619 -6,648 -2407,226 -2405,152 
21 #1.186 (87) 2 -6,663  -2404,115  
22 #1.195 (96) 2 -6,934 -6,942 -2407,691 -2407,695 
22 #1.193 (94) 2 -6,951  -2407,698  
24 
#1.206 (07, 08, 09, 
10) 5 -6,701 -6,740 -2407,076 -2407,156 
24 #1.203 (04) 2 -6,839  -2407,357  
27 #1.227 (28, 29) 3 -6,612 -6,622 -2406,918 -2406,828 
27 #1.232 (33, 34) 3 -6,632  -2406,738  
31 #1.253 1 -6,629 -6,629 -2402,833 -2402,833 
Total 
and 
average 
 
116 
-7,042 
 
N/A -2412,330 
 
 
 
 Cholesterol:      
Cluster Model Total 
number of 
models 
ΔG Average of 
the cluster 
FullFitness Average for 
the cluster 
7 #1.53(54 og 55) 3 -6,446047 -6,459 -2406,670 -2406,680 
7 #1.50 (51) 2 -
6,4792695 
 -2406,695  
12 #1.91 (92) 2 -
6,3395786 
-6,393 -2403,389 -2403,266 
12 #1.95 1 -
6,5003886 
 -2403,020  
16 #1.119 (120) 2 -6,489759 -6,546 -2402,580 -2402,544 
16 #1.121 (22, 23, 24) 4 -
6,5746174 
 -2402,525  
17 #1.132 1 -6,587872 -6,596 -2401,511 -2402,786 
17 #1.128 (29, 30, 31) 4 -6,598333  -2403,104  
18 #1.138 (39, 40) 3 -6,314338 -6,367 -2402,367 -2402,692 
18 #1.133 (34) 2 -6,446011  -2403,179  
19 #1.147 (48) 2 -6,172285 -6,174 -2402,331 -2402,339 
19 #1.141 1 -6,178  -2402,356  
20 #1.154 (55, 56) 3 -6,223 -6,242 -2401,659 -2401,828 
20 #1.149 (50, 51, 52) 4 -6,255  -2401,955  
21 #1.157  1 -6,439 -6,464 -2401,677 -2401,638 
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21 #1.160 1 -6,488  -2401,6  
22 #1.165 (66, 67, 68) 4 -5,687 -5,773 -2401,087 -2401,240 
22 #1.161 (62, 63) 3 -5,887  -2401,444  
23 #1.171 1 -6,448 -6,494 -2400,12 -2400,925 
23 #1.169 (70) 2 -6,517  -2401,327  
24 #1.176 (77) 2 -6,157 -6,168 -2400,553 -2400,531 
24 #1.178(79, 80) 3 -6,175  -2400,517  
25 #1.187 (88) 2 -6,541 -6,541 -2399,377 -2399,377 
26 #1.189 1 -6,038 -6,102 -2400,107 -2399,820 
26 #1.190 (91) 2 -6,133  -2399,677  
27 #1.198 (99, 200) 3 -6,325 -6,326 -2399,895 -2399,938 
27 #1.193 (94, 95) 3 -6,327  -2399,981  
28 #1.201 (202, 203, 
204) 
4 -6,462 -6,464 -2399,737 -2399,721 
28 #1.205 (06, 07) 3 -6,467  -2399,700  
30 #1.223 (24) 2 -6,338 -6,405 -2398,123 -2398,504 
30 #1.220 (21, 22) 3 -6,451  -2398,757  
31 #1.225 1 -6,380 -6,429 -2398,804 -2398,384 
31 #1.230 (31, 32) 3 -6,446  -2398,244  
33 #1.247 (48) 2 -5,932 -5,949 -2396,591 -2396,712 
33 #1.241 (42, 43, 44) 4 -5,957  -2396,772  
34 #1.254 1 -6,427 -6,513 -2396,562 -2396,627 
34 #1.249 (50, 51, 52, 
53) 
5 -6,531 -6,459 -2396,640  
Total 
and 
average 
 90 -6,317 
 
N/A -2400,72 
 
 
Appendix #4 
Cholesterol molecule used in the docking analyses -ZINC4175349: 
 
27-hydroxycholesterol molecule used in the docking analyses - ZINC4097086: 
 Page 69 of  75 
 
 
Methylphenidate molecule used in the docking analyses – ZINC896709: 
 
Appendix #5 
hCES1 has, as 3A4 and 2D6, some xenobiotic inhibitors. These are shown below in Table 9.  
Table 9: Substrates that causes an inhibition of hCES1 
Substrate Reference 
Clopidogrel (Shi et al., 2006) 
Ethanol (Laizure et al., 2003) 
Israpidine (Thomsen et al., 2014) 
Nelfinavir (Rhoades et al., 2012) 
Procainamide (Bailey and Briggs, 2003) 
Tacrine (Bencharit et al., 2003) 
Tacrolimus (Thomsen et al., 2014) 
Quinidine (Bailey and Briggs, 2003) 
 
